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Improving Prostate Cancer Detection in Veterans through the Development of a Clinical
Decision Rule for Prostate Biopsy
Captain Owen T. Hill, PA-C, MPAS
ABSTRACT
In the U.S., the number of prostate biopsies increases annually. This is partly due
to elevated prostate specific antigen (PSA) values identified during PC screening.
This study’s goal was improving prostate cancer (PC) detection through
developing a clinical decision rule (CDR), based on an elevated PSA and laboratory
biomarkers. This decision rule could be used after an elevated PSA, providing the patient
and clinician information to consider prior to biopsy. This cross-sectional study evaluated
men from the Tampa, Florida, James A. Haley (JH) VA (N=1,378), from January 1,
1998, through April 15, 2005.
The study hypothesized that specific lab biomarkers among JH VA PC cases
would differ significantly from JH VA patients without PC. The following biomarkers
were related to PC: hemoglobin (HGB) (OR=1.42 95%CI 1.27, 1.59); red blood cell
count (RBC) (OR=2.52 95%CI 1.67, 3.78); PSA (OR=1.04 95%CI 1.03, 1.05); and,
creatinine (OR=1.55 95%CI 1.12, 2.15).
This study attempted to determine whether including specific biomarkers (that are
related to systemic diseases associated with advancing PC) could improve PC prediction
(versus PSA alone). Comparing all PC stages versus non-cancerous conditions, the
Receiver Operator Characteristic (ROC) curve area under the curve (AUC) expanded
x

(increasing the probability of correctly classifying PC): PSA (alone) 0.59 (95% CI 0.55,
0.61); CDR model 0.68 (95%CI 0.65, 0.71), and the positive predictive value (PPV)
increased: PSA 44.7%; CDR model 61.8%. Comparing PC (stages B, C, D) vs. other, the
ROC AUC increased: PSA (alone) 0.63 (95% CI 0.58, 0.66); CDR model 0.68 (95% CI
0.68, 0.75), and the PPV increased: 20.6% (PSA); CDR model 55.3%.
These results suggest evaluating certain biomarkers might improve PC prediction
prior to biopsy. Moreover, the biomarkers may be more helpful in detecting clinically
relevant PC. Follow-up studies should begin with replicating the study on different U.S.
VA data-sets involving multiple practices.
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Chapter I: Introduction
In the United States, the number of men who undergo prostate biopsies to rule out
prostate cancer (PC) increases annually.1 This is in large part a result of elevated serum
prostate specific antigen (PSA) values identified during routine screening for prostate
cancer. Debate over the appropriateness of prostate cancer screening is ongoing.1, 8, 11 In
addition; there is controversy over the proper course one should take upon detecting PSA
elevations.8 Moreover, deliberation continues over whether prostate cancer qualifies as a
disease eligible for screening. Lastly, it is inconclusive whether early prostate cancer
detection truly results in lower morbidity and mortality for the men identified. 1, 8, 11, 15
Despite the wide spread use of the PSA screening test in the medical community,
the U.S. Preventive Task Force (an agency that provides medical screening guidance)
state the following, "routine screening for prostate cancer with digital rectal examination
(DRE), serum tumor markers (PSA), or transrectal ultrasound (TRUS), is not
recommended".2 Additionally, the National Cancer Institute, World Health Organization,
Canadian Cancer Society, and International Union against Cancer do not support the
routine screening of men for prostate cancer. Conversely, the American Cancer Society,
American College of Radiology, and the American Urological Association do
recommend screening men above the age of 50 with a routine PSA serum draw and a
DRE.16
The contrasts in the above recommendations demonstrate the diverse views that
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exist in the medical community on prostate cancer screening. Proponents’ for routine
prostate cancer screening argue that screening is a valuable early detection tool because it
can identify PC in asymptomatic men prior to clinical presentation. Earlier identified PC
should be at a less advanced stage, which implies a more treatable state. There is
evidence that supports this claim, demonstrating longer survival in patients with earlier
identified disease.17 In a 1996 study looking at racial differences in prostate cancer
screening, a statistically significant stage shift towards less invasive disease was
discovered when evaluating men who were screened verses those not screened (or who
had PC recognized by other methods than screening; i.e. clinical identification). Ninety
percent of prostate cancer identified through screening were localized within the prostate,
much more than that of clinical identification.17 It is estimated that men who are
diagnosed with non-palpable tumors (stage A-organ confined) have a survival rate of 87
percent, while metastatic PC (stage D) survival rates are approximately 30 percent.4
Additionally, for the majority of cases, type A tumors have lower Grade status
(determined by the Gleason score), lending themselves to be better candidates for
curative treatments.16 This data is controversial however, due in part to two major issues.
The first revolves around the unknown path many of the stage A PC tumors (small and
prostate confined) can take. Prostate cancer can be very slow growing, and in many cases
never becoming clinically evident. In a study of PC identified on autopsy, 30 percent of
men over the age of 50 had histological evidence of prostate cancer.5 In an additional
study of elderly men and prostate cancer, 57 percent of men over the age of 80 had
prostate cancer identified by step section biopsy.46 Secondly, categorizing all PC as
‘prostate cancer’ can be misleading. Not all prostate cancer act in the same fashion. Many
2

prostate cancers are indolent, with a high likelihood of never becoming clinically
relevant. Conversely, an aggressive PC may rapidly advance from a pre-clinical state to
invading organs in a metastatic fashion.16
An essential goal of prostate cancer screening is to identify PC that would
progress to clinically evident disease, the most deleterious form of prostate cancer.
Unfortunately, as it stands today, prostate cancer screening has not been able to
consistently delineate these tumors from the non-deleterious variety. As a result, a
multitude of unnecessary, potentially life altering prostate procedures continue to occur.
A major concern with PC screening is proper classification of disease severity.
Simply identifying ‘prostate cancer’ is not enough information to determine the
appropriate course of treatment. A study performed in 1994 provided insight on the
current ambiguity that surrounds prostate cancer. The study looked at the impact stage A
PC had on men who elect for radical prostatectomy surgery. Twenty-six percent of the
157 men who had undergone radical prostatectomy were afflicted with insignificant
disease.5 In addition, researchers from a 1998 study demonstrated that 84 percent of men
within their study population would not benefit from radical prostate surgery.22 This data,
coupled with prior research that demonstrates poor validity and reliability, makes using
PSA alone a very suspect screening tool for prostate cancer detection.7, 43, 116
Prostate Cancer Epidemiology
Prostate cancer is the second leading cause of cancer death in men in the United
States, accounting for 40,400 cases in 1995, and 8,500 in the United Kingdom.6,10,15 It is
the most common cancer detected in American men, with more than 230,000 cases
detected each year.6 It is also the most commonly diagnosed non-skin cancer in most
3

developed countries.10 Over a 10 year period (1985-1995), the reported incidence has
increased from 85,000 to 244,000.25 The annual incidence of PC does not match the
prevalence identified on autopsy, where PC is present more than 40 percent of the time in
men aged 60 years or older.7 It is primarily a disease of elderly men, with PC mortality
age distribution demonstrating this well. Eight-five percent of men who die from PC are
above the age of 65.6 Specifically, men aged 75-84 years of age account for the highest
percent percentage of death (41.7 percent), men 55-64 account for 7.4 percent, 65-74
(28.4 percent), and 85 or greater (21.4 percent), respectively.7 Younger men (less than
55) account for only 1.1 percent of the total prostate cancer mortality numbers.18
Screening Criteria
One function of a screening test is to identify the disease of interest in persons
who are currently asymptomatic and would progress to a clinically evident case if not
without early identification. For screening to be effective, it must be performed on a
repetitive basis.19 For screening to be cost-effective, it must be readably available, quick,
and be of little risk.19 In prostate cancer, if biopsies were performed on all men instead of
utilizing surrogate markers (i.e. PSA and/or DRE); the assumed result would be better
reliability and validity. This idea is impractical, given the number of potential problems
seen with prostate biopsy. Known prostate biopsy morbidities include infection, bleeding,
incontinence, acute and chronic pain.
Risk Factors of Prostate Cancer
The causes of prostate cancer are currently unknown. Known associated risk
factors for prostate cancer include increasing age, family history, and ethnicity.
Additional risk factors described with PC include environmental exposures, smoking,
4

dairy products, red meat, animal fat, and biologically plausible fetal exposures (both
environmental and genetic).10
Research Question/Study Design
The overall goal of this study is to improve the efficiency of PC detection
through the development of a clinical decision rule that is based on an elevated PSA and
set of laboratory biomarkers. This measure would be used as a secondary screening test
(after an initial PSA test) that the patient and clinician can refer to for additional
predictive information before undergoing a prostate biopsy. This is a cross-sectional
study, evaluating men from a reference population within the VA healthcare network
from January 1, 1998 through April 15, 2005. The men are between 40-90 years of age,
prior military servicemen who utilize the Tampa Veterans Administration medical
network for their healthcare needs. These men have undergone prostate biopsies as a
result of an elevated PSA screening test (>4ng/dL) The subjects are classified into one of
four ‘histology’ groups: biopsy confirmed prostate cancer (PC); biopsy confirmed
Prostatic Interstitial Neoplasm (PIN); biopsy confirmed Benign Prostatic Hypertrophy
(BPH); or biopsy confirmed PC negative/BPH negative/PIN negative, to accomplish
three specific aims.
Aim 1 – The first aim is to identify biomarkers that are both related to prostate cancer and
have the capability of improving the efficiency of PC screening. Within the prostate
biopsied groups of men, evaluation of routinely ordered laboratory biomarkers
(hematologic, serologic, and urologic) will be performed to assess for significant
relationships between the biomarkers and histology groups.
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Hypothesis 1: Among VA patients who have undergone prostate biopsies secondary
to a PSA value of >4ng/dL, specified lab biomarkers* among cases of prostate
cancer will differ significantly from those among VA patients without prostate
cancer.
Aim 2 - Upon completion of the above aim, statistical models (including biomarkers and
known PC risk factors) will be developed to determine which can best predict the
probability of prostate cancer. These potential screening models will be compared to the
current screening tool (PSA only), to evaluate for improved overall effectiveness in
prostate cancer detection and reduction in prostate biopsy. The inclusion of additional
predictors offers potential for decreasing unnecessary prostate biopsies and false positive
tests; resulting in increased specificity, predictive values, and better overall validity.
Hypothesis 2: Among VA patients who have undergone prostate biopsies secondary
to a PSA value of >4ng/dL, the addition of specified lab biomarkers* will improve
the effectiveness of predicting the presence of prostate cancer when compared to
PSA alone.
Aim 3 - The third aim of this study is to assess for a dose-response relationship between
specified lab biomarkers (surrogates for extra-prostatic disease development) and the
progression of prostate cancer. If present, this parallel progression would demonstrate a
gradient between PC and systemic disease. For example, as a patient afflicted with
prostate cancer progresses through stage A to stage D, development of other systemic
diseases (i.e. Iron Deficiency Anemia), would follow a similar progression of disease
severity. Thus lab values associated with these systemic diseases should move further
from there “normal” values. If this relationship can be demonstrated, it would be possible
6

to classify PC patients in terms of likely benefit from invasive interventions verses
employing an expectant observation approach.
Hypothesis 3: Among VA cases of histologically confirmed prostate cancer, there
exists a gradient between specified lab biomarkers* and increasing stage of prostate
cancer.

7

Chapter II: Literature Review
The ideal prostate cancer screening tool would be one that identifies men with
prostate cancer that is not yet clinically evident. The test characteristics would include a
very high validity (demonstrated thorough high sensitivity and specificity), reliability,
and predictability. It would be relatively inexpensive (when compared to follow-up
diagnostic tool), minimally invasive, and readably available. Additionally, upon its
implementation, mortality and morbidity rates secondary to prostate cancer would
decrease with time. Unfortunately, we currently do not have such a screening tool. As a
result, researchers are continuously looking at ways to improve prostate cancer screening.
Prostate Cancer Screening Tools
PSA
Prostate specific antigen is protein generated out of the epithelial tissue of the
prostate. It is released primarily from the transitional zone of the prostate.41 Multiple
biological processes can elevate serum PSA. Cancer, BPH, acute bacterial prostatitis,
chronic bacterial prostatitis, nonbacterial prostatitis, prostate stones, urinary tract
infections, ejaculation, bicycle riding, and manual manipulation are all examples of
potential sources of PSA elevation.1
PSA is a gene product from chromosome 19 and has a molecular weight of
34,000.43 PSA is typically bound to protease inhibitors upon entry into systemic
circulation.68 The newly bound, ‘complexed PSA’ (cPSA), most often partners with the
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a1-antichymotrypsin (ACT).68 Prior research has demonstrated that the ACT form of PSA
occurs more often in men with prostate cancer.69
Prostate specific antigen was first identified in 1979, and not long after its
discovery, researchers began to use it within prostate cancer screening. In 1986, the U.S.
Food and Drug Administration approved the first commercial immunoassay for use in the
treatment of prostate cancer patients.7
The serum levels of PSA correlates with the volume of both benign and cancerous
cells. PSA was first used as a screening test for prostate cancer in 1986.7 It was evaluated
again in epidemiologic research in 1987 and 1988, where it was examined for its
usefulness in clinic utilization as a predictor for final pathologic stage in patients with
localized PC, and after radical prostatectomy.7 In both cases, PSA was found to be a
useful tool in monitoring PC patients for detection of recalcitrant or recurrent prostate
cancer after radical prostatectomy.
PSA has been employed mostly as a tool for prostate cancer screening. Falsepositive results remain high with total PSA. It is estimated that 1 out of every 5 men who
have pre-clinical localized prostate cancer have a PSA value of less than 4 ng/mL.72 The
estimated positive predictive value of PSA (4ng/dL) is 30 percent.71 PSA is also used as a
tool for staging and for monitoring of cancer reoccurrence post prostatectomy.73 Prior
studies have demonstrated post radical prostatectomy, elevations of PSA are a reliable
and valid sign of recurrent cancer.73
Digital Rectal Exam
An additional prostate detection tool is the Digital Rectal Exam. Although the
sensitivity and specificity of digital rectal exam (in prostate cancer detection) is
9

considered poor, its relative convenience, lack of cost, and minimal side effects make
DRE a frequent tool utilized by practitioners in prostate gland evaluation. The DRE is the
most frequently performed prostate exam in clinical medicine today. Despite the lack of
accuracy, it is recommended by the American Cancer Society, American College of
Radiology, and the American Urological Association that all men above the age of 50
undergo routine annual DRE.16 Although previous studies on DRE sensitivity and
specificity vary widely due to the specific population under study, a study performed in
1988 estimated the sensitivity at .8 percent and specificity at .25 percent, respectively.61
The positive predictive value is also mottled, with studies demonstrating PPV values
from 6 to 50 percent.30, 61, 62
On physical exam, the posterior wall of the prostate gland can be palpated.4
Prostate cancer arises primarily within the periphery of the gland, thus allowing for
potential identification of large tumors by DRE. The characteristics of a prostate mass
have been previously described as indurated, poorly differentiated, and hard.63
Prior studies have demonstrated many limitations of DRE. These limitations
include poor identification of small, organ confined tumors, selection biases (on age and
subjective history), and variability due to the skill level of the practitioner performing the
exam.63
PSA Velocity
Over the last decade, the rate of PSA change has been gaining interest as a
potential predictor of early prostate cancer. In a 2004 study recently published in JAMA,
researchers found that the way PSA levels change over time (velocity) may be a more
important factor than any specific level of PSA.23 This prospective study included 1,095
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men who had undergone radical prostatectomy. The authors reported that the risk of
death secondary to metastatic prostate cancer was directly related to the rate of velocity
change in sequential PSA serum levels, which appeared to be more accurate than
standard PSA testing alone. Comparing men whose PSA increased 2 ng/dL or greater to
men without change in their PSA levels, the risk ratio (IDR) was found to be 2.8. This
implies men with rising PSA values are nearly three times more likely to die within seven
years of radical prostatectomy (than men without rising PSA values).23
PSA velocity is defined as the change of PSA value over a defined time period.7 It
is theorized that the PSA levels which increase more rapidly than expected over a
specifically defined time period are more likely to be caused by prostate cancer than a
benign, less aggressive prostate problem. PSA velocity is normally assessed by
determining the percent change in serum PSA levels over a year basis. The ‘acceptable’
rate of change is still open to debate, although a change of greater than or equal to
.75ng/dL per year is highly suspicious of prostate cancer.26
Carter et al. were the first to assess the functionality of PSA velocity change as a
potential tool for prostate cancer detection. This retrospective study looked at 54 serum
samples taken from men enrolled in the Baltimore Longitudinal Aging Study. The
evaluated men were grouped as biopsy confirmed prostate cancer patients, BPH patients,
or the control group. In men whose PSA levels were below the elevated ‘positive’ marker
(4ng/dL), it was shown that an increase of .75 ng/dL or greater would identify PC in men
with a test sensitivity and specificity of 80 percent and 66 percent, respectively.26 PSA
velocity identified prostate cancer cases from non-cancerous disease with a specificity of
90 and 100 percent when evaluating accrued PSA levels.26 Their discussion centered on a
11

potential biopsy reduction of upwards of 30 percent among men with a prior negative
biopsy and persistently elevated PSA levels. Additionally, when compared to the
standard total PSA serum evaluation, PSA velocity may be a more valid early identifier
of prostate cancer.
A considerable drawback to the widespread use of PSA velocity is the intraindividual variation in men with regards to their PSA values. This variation is irrespective
to the state of disease within the prostate. A change of .75ng/dL might be predictive of
prostate cancer, but as described by Carter et al., three consecutive PSA measurements
are needed over an 18 to 24 months time window to clearly distinguish the prostate
cancer cases from that of the non-cases.27 Given this key data, it is unlikely that PSA
velocity (in its current form) will be incorporated in a national prostate cancer screening
program as a substitute (or adjunctive) tool for total PSA.
Age specific cut-off points
Many researchers and clinicians have advocated the use of age specific
cut-off ranges as a way to better to screen for prostate cancer.86 Proponents for this
screening method argue that using a higher cut-off point for older men will not result in
increased PC morbidity and mortality events. It has been previously established that the
prostate size increases with age. As the volume of prostate tissue increases with aging, so
does the potential for elevated PSA values.85 The hypothesized benefit of having a higher
cut-off value for older men is an overall drop in the number of unnecessary biopsies that
would occur each year.84 Additionally, using a cut-off value that is under 4 ng/dL for
younger men would increase the likelihood of detecting asymptomatic tumors. It is a
given that younger men have a longer life expectancy than older men, and proponents
12

believe it is more important to detect the disease in the young. This increased life
expectancy places them at increased risk of prostate cancer development, progression,
metastasis, and death.27
Over the last 12 years, published studies have produced conflicting data on this
topic. Initially, it appeared that results from a 1993 study pointed towards potential
improvement in disease detection with the utilization of age specific cut-off points.27 The
study by Oesterling et al., focused on developing the specific cut-off point values. The
researchers found that by increasing the cut-off points as the age groups increased, the
number of unnecessary biopsies could be reduced. Moreover, the large percentage of
missed prostate cancers was classified as ‘not clinically important’. For example, within
the 60-69 age strata, nearly 20 percent of all biopsies would not have been performed,
resulting in missing less than 5 percent of the total tumor amount (within the evaluated
age strata). Additionally, 95 percent of the ‘missed’ cancers were deemed ‘clinically
irrelevant’.27 In their follow-up study, the following age specific PSA levels were detailed
and recommended:
40 to 49 years of age

PSA value 2.5ng/dL or greater

50 to 59 years of age

PSA value 3.5ng/dL or greater

60 to 69 years of age

PSA value 4.5ng/dL or greater

70 to 79 years of age

PSA value 6.5ng/dL or greater

Table 1. Age-Specific Reference Ranges: (Partin and Oesterling et al., 1996).
The authors stated by initiating the above cut-off values in place of the standard 4ng/mL,
an additional 74 men (who had values below 4ng/dL) of the nearly 4,600 males sampled
would have been identified as having prostate cancer.27 Of these 74 men, 14 were
13

identified as having ‘unfavorable pathology’, indicating increased likelihood that their
tumor would cause significant morbidity or mortality if left untreated. The authors
concluded that by incorporating the age specific reference ranges in conjunction with
DRE, younger men at higher risk for prostate cancer development would be identified,
and elderly men would be less likely to undergo unnecessary biopsies. They additionally
stated that elderly men were more likely to present with less aggressive cancer when
compared to their more youthful counterparts, providing more evidence to support
changing the reference ranges.27
However, over the last decade numerous new studies have been published that
seem to suggest age-specific cut off points are problematic. These studies demonstrate
that many of the older men in the study in fact had aggressive tumors, often with Gleason
score 7 or greater in grade type. A 1998 study reported that of the men who would not
have been biopsied on the age-specific reference range algorithm, 1 out of 5 had
‘aggressive cancer’.84 Similar findings have been additionally published, demonstrating
the potential for a total biopsy reduction of 8 to 15 percent, but with 15 to 30 percent of
clinically important cancers being overlooked.85, 86 As a result of the inconsistent findings
between published research, incorporation of age-specific cut-off values has been met
with skepticism and has not occurred on a national level.
PSA Density
PSA density is determined by dividing the total PSA by the prostate volume.42 It
has been suggested that the PSA density could control for total PSA increase related to
the natural prostate enlargement correlated to age. PSA density was first reported to
delineate between elevations related to prostate cancer and BPH in 1987.39 The
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researchers concluded that after controlling for confounding factors, PC is ten times more
likely to be the underlying etiology of total PSA elevations when compared to BPH. To
further strengthen the PSA density role in delineating PC from BPH, researchers in a
1992 study of men referred to Urologic specialty center found that PSA density could
better differentiate PC cancer patients from BPH patients.40 The study looked at 595
patients who had an initial total PSA value of between 4-10 ng/dL. Evaluating men who
had either prostate cancer or BPH, there was a statistically significant difference in the
PSA density between the two groups (p<0.001), while the difference of the total PSA
between the two groups was not.40 Furthermore, additional studies found significant
differences exist in the PSA density of men with PC compared to non-cancerous prostate
conditions, although statistical significance could only be found in the 4 ng/dL groups.41
Recent PSA density research has looked more closely at the transitional zone
volume as opposed to the volume of the entire prostate. The transitional zone is one of
three distinctive histologic regions within the prostate.41 The two additional regions
include the peripheral and central zones. It is believed the transitional zone constitutes
less than 5 percent of the total volume of the prostate.41 Given that the majority of
prostate tissue growth and PSA outflow occurs in the transitional zone, it has been
hypothesized that focusing on this particular region as opposed to the entire gland might
result in better prostate cancer prediction. A 1998 study looking at transitional zone PSA
density and percent free PSA with and without total PSA demonstrated that at 0.22 ng/dL
or above, transitional zone PSA density would have prevented almost 25 percent of all
evaluated negative prostate biopsies would have been avoided.42
The limiting issue surrounding the widespread use of total prostate PSA density
15

and transitional zone PSA density is that they both require ultrasound imaging of the
prostate for the accurate determination of prostate volume. The most common ultrasound
imagining available is the Transrectal ultrasound (TRUS), and it has previously reported
that the volume calculations obtained from the TRUS are not always exact, further
limiting its implementation. At this time the recommended usage of PSA density is for
the recalcitrant PSA elevations with a previous negative biopsy for prostate cancer.16
Gleason Score
An important predictive characteristic of prostate cancer is the appearance of the
glandular tumor cells (which assists in defining the aggressiveness of the cancer). The
Gleason score was derived to describe the microscopic appearance of the glands that
form prostatic cancer.106 Prostate cancer of a low-grade is less likely to spread, while
increasing grades are at higher risk of metastasis.16 The Gleason score is based on the two
most prominent areas of PC activity as identified by a pathologist on histologic
examination.4 Each prominent area is given a score of 1-5, with 1 being well
differentiated, and 5 being poorly differentiated (implying a more aggressive
appearance).4 The two scores are added together, and this number is called the “Gleason
score”.106
A Gleason score of 2-4 is considered low grade (less aggressive); 5-7 is
considered moderate grade (average aggression); and a Gleason score of 8-10 is
considered high grade (most aggressive).16 A man with a Gleason score above 7 is at
increased risk of dying from PC than a man with a Gleason score of 7 or below.106
Transrectal Biopsy
In an attempt to heighten the understanding of prostate tumor location,
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aggressiveness, and increase accuracy in determining PC presence, ultrasound guided
transrectal prostate biopsy has been incorporated into the standard of care for many PC
patients. Originally, prostate biopsies were performed through a transperineal approach.63
This technique was replaced due to the limited visibility it offered in terms of biopsy
needle placement. The transrectal biopsy has been demonstrated to be a superior tool in
providing information on appropriate needle placement in cases where prostate cancer is
suspected.62
The biopsy is performed with an 18 gauge, spring loaded needle. The biopsies are
performed in a systematic fashion, with an average of 6-10 sextant biopsies performed
per biopsy procedure.65 Controversy has increased recently over the amount and location
of the TRUS biopsies. Many PC experts recommend increasing the number of biopsies
performed per session, and increasing the area under evaluation. Typically the biopsies
are performed within the periphery of the gland, given that the majority of PC arises
within this prostate zone. However, many investigators have demonstrated that the rate of
prostate detection from biopsies is inversely proportional to the size of the prostate.63
PSA Elevators
Prostate Cancer
Prostate cancer is comprised of an assorted set of tumor subtypes. Although the
heterogeneity of prostate cancer is well documented, the natural history of the disease is
poorly understood. All types of prostate cancer are androgen dependent. The androgen
receptor is the prime regulator of both benign and cancerous prostate epithelial cell
growth.36 Upwards of 95 percent of all PC tumors are adenocarcinomas located along the
edge of the prostate.64 Greater than three quarters of prostate adenocarcinomas are
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multifocal in origin.45 Transitional cell tumors account for 4 percent of all PC, and
squamous cell tumors are very rare, making up the final 1 percent of the prostate cancer
total.
Extraprostatic extension of prostate tumors typically occur posteriorly and
posteriolaterally along a plane of least resistance into the perinueral space.65 Local
extraprostatic invasion commonly occurs in the seminal vesicle, urethra, bladder, and
often continue to the local lymphatic chains.
The skeleton is the most frequent system of distant PC metastasis. It has been
previously reported that upwards of 85 percent of patients dying of this cancer have bony
metastasis present. Additional systems associated with distant PC metastasis include the
lungs, brain, lymph nodes, and viscera.67
The tumor volume has been shown to correlate with its aggressiveness. Small
tumors are unlikely to spread outside of the prostate. Conversely, tumors that achieve
extraprostatic status and are greater than 4cc in volume are at increased risk for both
seminal vesicle and lymphatic invasion.66
Staging and grade of prostate cancer is summarized below:
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Stage A

Stage B

Non-palpable
confined to
prostate
Palpable confined
to prostate

Gleason
score 2-4
Gleason
score 5-6

Stage C

Locally spread
Gleason
outside of prostate score 7

Stage D

Distant metastasis

Gleason
score 8-10

Well
differentiated
cells
Moderately
differentiated
cells
Moderately
poorly
differentiated
cells
Poorly
differentiated
cells

Best prognosis

Better
prognosis
Guarded
prognosis

Poor prognosis

Table 2. Prostate Cancer Stage and Grade
Prostatic Interstitial Neoplasm (PIN)
Prostatic Interstitial Neoplasm is thought to be a precursor for prostate cancer.58 It
has been previously described as a proliferative mass made up of prostatic acini epithelial
cells that are dividing and multiplying at increased rates.57 The cells are not cancerous in
their morphology, although their presence on prostate biopsy suggests increased
probability that prostate cancer development will occur in the patient under evaluation.58
Prostatic Interstitial Neoplasm is a dysplastic lesion; classified as low (grade I),
medium (grade II), and high (grade III).57 Low grade PIN does not have the same
likelihood of progression to prostate cancer as medium and high grades.59 The reported
prevalence of medium grade PIN identified in benign prostates has been reported at 1070 percent, respectively.57 The prevalence of high grade PIN in cancer free prostates is
estimated to be between 15-20 percent.57 In specimens positive for prostate cancer, high
grade PIN it is identified in approximately 33 percent of autopsied samples, and 70-100
percent in surgical samples status post radical prostatectomy.59
Currently, prostate cancer clinicians and researchers do not have a universally
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recommend treatment regimen for Prostatic Interstitial Neoplasm.60 Chemoprevention, in
which androgen deprivation techniques are employed to decrease the progression of PIN
and possibly delay or arrest PC development, are currently under evaluation in clinical
trials. Radiation therapy has been reported to decrease PIN.60 Lycopene, soy, and certain
vitamins (D, E) have been previously identified as potentially protective in prostate
cancer development and therefore have been described as ‘potentially helpful’ in
preventing PIN development.56
Prostatic Interstitial Neoplasm follow-up is not clearly defined. In general, it is
recommended to have an additional trans-rectal biopsy within six months, and again
possibly every 1-2 years thereafter. Routine PSA draws are additionally recommended.60
The correlation between PIN and PSA elevations and the effect PIN has on
screening is poorly understood. In general, it is thought that prostatic interstitial neoplasm
does not elevate PSA levels.59 The screening for PIN is not recommended.58 Numerous
prospective studies on PIN are currently ongoing, but as of now the impact of PIN on
prostate cancer screening is unknown.
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy (BPH) is a frequent elevator of serum total PSA.87
The underlying etiology of BPH is poorly understood. Hypothesized etiologies include
endocrine activity, diet, activity, and familial genetic factors.88 The incidence of BPH is
related to increasing age.4 The prevalence of BPH follows a linear trajectory with age, as
BPH has been identified on autopsy in 22 percent of men aged 41-50 years old, with
linear increasement to over 75 percent in men older than 80 years.87 The genesis of
Benign Prostatic Hypertrophy is typically in the periuretheral and transitional zones of
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the prostate.89 Conversely, prostate cancer originates in the prostate’s peripheral zone.18
Subjective symptoms of benign prostatic hypertrophy are comprised of both
irritative and obstructive voiding complaints.88 Irritative symptoms include urinary
urgency, frequency, painful urination (dysuria), and increased urination at night
(nocturia).88 Obstructive symptoms include urinary hesitancy, weak urine stream,
intermittent voiding, and weakened voiding force.88
Clinical objective evidence of benign prostatic hypertrophy includes localized or
global enlargement of the prostate, as identified on digital rectal examination.88
Additionally, supra-pubic abdomen distention may be palpable, indicating urinary
retention secondary to the prostatic hypertrophy.90
Laboratory finding seen in conjunction with BPH include elevated PSA, blood
urea nitrogen (BUN), creatinine, and less commonly hematuria, positive nitrates, and
leukocytosis (if a urinary tract infection is concomitantly present).88
Imagining studies are frequently performed with benign prostatic hypertrophy. They
include Intravenous Urography, Uroflometry, and Cystourethroscopy.88 Uroflometry is
considered the most useful urodynamic tool in assessing the degree of BPH, with a urine
flow of less than 10mL per second indicating advanced obstruction secondary to the
prostatic hyperplasia.87
Treatments for benign prostatic hypertrophy fall into one of three broad
categories: medication, surgical, and minimally invasive treatments.87Medication
treatments include a multitude of androgen deprivation medications, although these
medications often result in decreased libido and sexual function.90 The prostate contains
a1adrenoceptors, that if blocked have been shown to result in contraction of prostate
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tissue.89 Therefore alpha1blockade medication has been shown to improve the irritative
and obstructive symptoms of BPH.89 Surgical treatments involves removal of the
enlarged prostatic tissue and can be performed through either the urethra or a traditional
incision.87 Transurethral resection of the prostate (TURP) has been identified as an
effective treatment of decreasing the symptoms of BPH with relatively low morbidity and
mortality statistics.87 The reported mortality rate is estimated 0.1 percent, with a
morbidity rate of less than 20 percent.89 The most common side effect of TURP is
retrograde ejaculation and bladder neck contracture.88
Additional minimally invasive techniques are currently under development and
offer the potential for decreased morbidity and quicker post-operative recovery. Balloon
dilation, ultrasound laser guided energy, and transrectal microwave hyperthermia are
some of the techniques currently under study.79 The use of these techniques is in the
investigational stage, with ongoing clinical trials results pending.79
Prostatitis is an inflammatory process of the prostate.80 It has been described
previously as one of three conditions: acute bacterial, chronic bacterial, and nonbacterial
prostatitis.80
Acute bacterial prostatitis
Acute bacterial prostatitis is characterized by complaints of fever; irritative
voiding symptoms, perineal pain, and exquisite tenderness on DRE.80 Urinalysis
frequently demonstrate pyuria, bacteriuria, and hematuria.79 Laboratory findings include
an elevated leukocytosis and left shift.79 Positive urine cultures are present, with the vast
majority of cases caused by gram-negative rod organisms.79 Specifically, Escheria coli,
Pseuedomonas, and (less commonly) Enterococcus are the most frequent causal
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organisms identified.78
The hypothesized routes of infection include refluxed infected urine into the
prostatic duct and an external infectious agent that ascents up the urethra.80 Differential
diagnosis for acute bacterial prostatitis include acute pylonephritis and acute
epididymitis.79 Treatments initially includes intravenous antibiotics and hospitalization.
Upon reaching afebrile status for 48 hours, oral antibiotics can then be initiated. Oral
antibiotics are commonly utilized for 4-6 weeks to ensure complete eradication of the
offending organism is achieved.80
Complications of acute bacterial prostatitis include urinary retention,
epididymitis, pylonephritis, and chronic prostatitis.80 With aggressive effective treatment,
complications are considered rare.79
Chronic bacterial prostatitis
Chronic bacterial prostatitis can arise secondary to an acute prostate infection, but
often times afflicted men have no history of such an event.80 Patients can be
asymptomatic, but they often complain of mild irritative voiding with dull suprapubic and
perineal pain.79 Urinalysis are often normal, but expressed prostatic secretions display
increased lipid-laden macrophage leukocytes (>10 per high powered field).79
The primary difference between acute and chronic prostatitis revolves around
treatment. Antibiotics have difficulty reaching therapeutic intraprostatic levels without
the acute inflammation seen with acute bacterial prostatitis.78 Therefore, treatment for
chronic bacterial prostatitis revolves around nonsteroidal anti-inflammatory
medications.78 Trimethoprim does penetrate the prostate, therefore it is often given for 34 months to complete the treatment regimen.80
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Nonbacterial Prostatitis
Nonbacterial prostatitis is the most common of prostatitis syndromes, and its
etiology is unknown.78 It is considered a diagnosis of exclusion, with some of the
hypothesized causes including viruses, sexual transmitted diseases, and autoimmune
disorders.78 Physical exam with nonbacterial prostatitis is similar to the chronic bacterial
condition, although prostatic secretion cultures are negative for organisms.78
Treatment for nonbacterial prostatitis include nonsteroidal anti-inflammatory
medications, sitz baths, and possibly dietary modifications if the symptoms seem to
correlated with food.80 Trials of antibiotics are encouraged if the condition is believed to
be secondary to a sexually transmitted disease.80 Unfortunately for many patients, this
condition is often recalcitrant to treatment and patients often experience recurrent bouts
of pain. Although annoying, serious morbidity secondary to nonbacterial prostatitis has
not been identified.80
In addition to the above known PSA elevators, it is believed that a recent digital
rectal exam, urinary tract infection, sexually transmitted disease, ejaculation, or extended
bicycle riding episode can all temporarily elevate PSA values as well.
Treatments for PC – confined to the prostate
Prostate cancer that is identified while confined to the borders of the prostate offer
more treatment options than a tumor that has spread locally or systemically. Younger
patients or patients with aggressive disease have many different options for their care,
and because there is not one overt superior treatment, the specific treatment course is
often determined by a patient’s decision. The treatment options for confined prostate
cancer can be grouped within two categories: radiation and surgery.
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Radiation treatments have two basic subcategories: internal and external radiation.
Internal radiation (Brachytherapy) is usually provided through radioisotopes needle
implants.43 Brachytherapy utilizes radioactive ‘seeds’, that are usually smaller than 2
millimeters in size, 75 to 100 of which can be typically implanted into the prostate during
the procedure.44 One significant advantage of internal radiation is that it is a one time
procedure, external radiation requires multiple treatments.10 External radiation relies on
imaging tools such as ultrasound, computed tomography (CT) scans, and pulse intensity
beams to assist in delivering high-dose beams of radiation to the prostate while protecting
the surrounding Genitourinary organs.44 This type of radiation treatments lasts
approximately two months, and usually includes over 40 treatment encounters.46
Radical Prostatectomy is the most common surgical approach in removing
prostate cancer from a patient.45 There are a multitude of surgical approaches with this
surgery, but the two most common approaches are the retropubic approach and the
perineal approach.81 The former is used when there is a need for lymph node biopsy,
while the latter is an acceptable approach for organ confined; low-risk disease is
present.81
Over the last decade laparoscopic surgery has been used more frequently for
radical prostatectomy surgery.45 This type of procedure is gaining in acceptance because
there is reportedly less blood loss during surgery, and less post-operative complications.45
Access to the lymph nodes for sentinel and multiple node biopsy is maintained, and
patients return to activities of daily living on average two weeks faster than the traditional
surgery. The primary drawback to this technique is the highly technical nature of the
procedure, which limits the number of surgeons qualified to perform the surgery.
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Cryosurgery is a technique in which the prostate is frozen by liquid nitrogen (or
argon gas); killing the cancerous tumors while limiting the destruction of healthy tissues
to a minimum.45 This technique uses ultrasound and MRI to guide the cryoprobe as it
distributes the liquid nitrogen. This surgery is a safe alternative for patients who are not
candidates for traditional surgery or radiation, and the procedure can be repeated if
deemed necessary. Disadvantages of cryotherapy include potential for incontinence,
impotence, and urinary obstruction. Due to its relative newness, the long term outcomes
of cryosurgery is unknown.46
For men afflicted with prostate cancer which is small, organ confined, and
asymptomatic, expectant observation is often employed.81 Additionally, men with a life
expectancy of ten years or less, or patients with comorbidities that suggest they are likely
to die from something other than their prostate cancer, often employ this strategy as
opposed to more aggressive treatment options.81 The focus for these patients usually
centers around quality of life, healthy lifestyles, with bi-annual PSA evaluations to
monitor their disease status. Benefits of watchful waiting include the avoidance of
surgical and radiation side-effects, avoidance of prolonged recovery period, and the
potential to maximize their quality of life. Disadvantages of expectant observation
include the lost benefit from early treatment, metastatic spread of the tumor, and early
than expected death.81
Local Spread treatments
Prostate cancer that has penetrated the external capsule of the prostate is treated
differently than organ confined disease. Commonly, locally spread PC is described as
having either ‘minimal capsular penetration’ (MCP), or ‘extensive capsular penetration’
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(ECP). The ECP subset includes PC that has invaded the seminal vesicle, bladder neck,
or both.77
The treatment options for patients of both categories are quite extensive. Radical
prostatectomy with inclusion of surrounding structures is the typical surgical treatment
for the MCP subset. For men with ECP, the benefit of radical prostatectomy surgery is
questionable. Prior research has demonstrated an increased risk of PC relapse for men in
this subset.82 In a retrospective study looking at ten year follow-up data, researchers
found that 46 percent of post-radical prostatectomy patients with low grade, locally
spread disease, had PC relapse within ten years. In addition, the same study determined
that 58 percent of post-radical prostatectomy patients with high grade disease
demonstrated clinical evidence of PC within the ten year time period.95
Many additional nonsurgical treatments are routinely employed for locally spread
PC. These treatment options include irradiation, hormone therapy, cryosurgery, and
combination therapies (androgen deprivation combined with medication, surgery or
irradiation).
The application of nonsurgical treatment modalities for locally spread PC has
increased significantly over the last ten years. Prior studies have shown survival rates of
nonsurgical treatments to be similar with that of radical prostatectomies, without the
associated morbidities that are often seen with major surgery.77 The use of nonsurgical
monotherapies is controversial in that relapse disease has been reported to be high
(relative to combination therapy). Relapse of PC within ten years is estimated at 55-65
percent for patients receiving radiotherapy as a single treatment agent.93
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Distant Spread
Metastatic PC treatments focus on palliative and combination therapies. The
typical first line treatments center on decreasing circulating androgen levels.92 PC is
hormone dependent, and the decrease of androgens will slow its spread. A primary
therapy of metastatic PC is the gonadotrophin releasing hormone (GnRH) analogous. In
survival analysis studies evaluating patients with metastatic prostate cancer treated with
GnRH, estrogen, or orchiectomy, significant differences in survival time were not
observed.94 This data, coupled with the known cardiovascular risks of estrogen, and the
general patient disdain for orchiectomy, has made GnRH compounds well liked by both
PC clinicians and patients.
Anti-androgens are commonly used as a part of a combination treatment regimen
for advanced PC. Prior clinical trials have shown Flutamide and Cyproterone (commonly
used anti-androgens) to be correspondent to estrogen in their anti-androgen actions with
decreased cardiovascular risk profiles.93 They are not without side effects, however, as all
medications within this class demonstrate varying degrees of gynocaemastia, gastrointestinal derangement, and erectile dysfunction.93
Hormone therapy has been associated with improved PC survival time if used in
combination with other treatment modalities.93 Finesteride is a 5-alpha reductase inhibitor
that acts by blocking the conversion of testosterone to dihydrotestosterone.94 Clinical
trials looking at Finesteride are currently underway, with early results demonstrating
evidence of a synergistic interaction between it and traditional anti-androgen
medications.
Chemotherapy is utilized as both a combination therapy option and as a single
28

agent medication. Although palliative benefits have been realized (when used in
combination with steroids), increased survival has not been demonstrated.92
Prostate Cancer Relapse
Relapse of PC (post primary treatment) does occur, with prevalence rates
estimated at 11 percent for patients with a pre-operative PSA velocity of 2ng/dl/year or
less.11 When relapse occurs, the median time until early biochemical activity is 2 years;
with the median time until clinical evidence at approximately 3 years.93 Upon detection
of relapse (increasing PSA values on three consecutive tests), a multitude of different
treatments can be initiated. Castration, in combination with androgen blockers,
corticosteroids, and radiotherapy, is often employed. Radiotherapy in particular is
beneficial in patients with skeletal metastasis. Many advanced therapies for both
metastatic and relapsed PC are limited secondary to high cost and geographical
availability.
Hematologic Complications of Prostate Cancer
It is known that patients with prostate cancer routinely present with complications
outside of the prostate. Patients with advanced prostate cancer often present with
objective hematologic findings that are secondary to either the side effects of PC
treatment, unrelated causes, or the cancer itself.29 Despite this commonly known fact,
(and fruitful advances in other areas of prostate cancer research), the relationship between
serologic and urinary disorders and prostate cancer has been largely ignored.
It is also known that PSA values can be elevated due to a many prostate
conditions, but it is unlikely that PSA elevations secondary to non-cancerous etiologies
will cause changes to other body systems (represented by the lab biomarkers). In prior
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published research, advanced prostate cancer has been indisputably identified as a cause
for such laboratory changes. In a study performed by Strum SB, et al, anemia in varying
severity was found as a frequent complication of advanced prostate cancer. The two
primary types of anemias found with prostate cancer are Iron Deficiency Anemia (a
subset of microcytic anemia), and anemia of chronic disease (either
normocytic/microcytic anemia).
The following is a description of hematologic conditions and laboratory
biomarkers that have been associated (directly or indirectly) with prostate cancer.
Anemia
Anemia is a known frequent complication of prostate cancer.32 Upon
identification of anemia in a prostate cancer patient, it is important to correctly diagnosis
the sub-category present, as the underlying etiology is then more easily identifiable. In
the presence of prostate cancer, anemia is likely a result of the prostate tumor itself, the
provided treatment, or secondary to an unrelated biological process.29 Iron deficiency
anemia (IDA) is the most common type of anemia found in medicine, and in prostate
cancer as well. Iron deficiency anemia is a sub-type of the Microcytic anemia group.30
Microcytic anemia is defined as an anemia with a mean corpuscular volume of under
80fL.33 Thalassemia is another commonly found type of Microcytic anemia, although it
correlation with prostate cancer is rare.33 IDA in any type of cancer patient is frequently
associated with chronic covert blood loss from either the genitourinary or gastrointestinal
tract.29 Anemia secondary to a local prostate tumor extension into the rectum and/or
colon resulting in bright red rectal bleeding has been reported.92
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Hemoglobin
Hemoglobin is a protein that carries oxygen from the lungs to the tissues and
organs of the body, and it also transports carbon dioxide to the lungs for exhalation. A
hemoglobin test value measures the amount of hemoglobin in the blood sample. A value
less than 13.8 gm/dL indicates a value out of the normal reference range and is an
indicator of potential hematologic problems.
Hemoglobin has been studied as a predictive factor in recalcitrant prostate
cancer.34 Multiple published studies have reported that a low hemoglobin value is an
independent risk factor for deleterious survival outcomes in patients with hormone
refractory prostate cancer.91 It has been hypothesized that prostate cancer cells can exert
an effect on bone marrow that depresses normal erythropoieses synthesis, resulting in the
decreased hemoglobin values. The effect of prostate cancer on hemoglobin as it relates to
prostate cancer screening and disease aggression has not been thoroughly evaluated.
Hematuria
Blood may appear in the urine as a result of numerous medical conditions,
including cancer of the prostate.33 Additional known common risk factors for hematuria
in men include: internal trauma, kidney stones, vigorous exercise, urinary tract infections,
prostatitis, glomerulonephritis, and cancers of the bladder, ureters, or kidneys.33
Hematuria is a rare initial clinical presenting complaint with prostate cancer, but
is a common finding in patients with prostate tumors that have spread outside of the
prostate capsule, but has not yet spread to distant body regions.33 Gross hematuria in an
adult male should be considered secondary to malignancy until proven otherwise.47
Terminal hematuria has been correlated in prior research as more likely related to bladder
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neck or a prostatic source then initial void hematuria. Terminal hematuria is defined as
the presence of blood at the end of the urinary stream.51
Urea Nitrogen (BUN)
Amino acids from endogenous sources and exogenous proteins generate NH3,
which is then converted to urea by the hepatic cells. Patients with minimal varying
degrees of urinary retention or with concealed ureteral obstruction secondary to prostate
cancer may present with elevations in serum urea nitrogen.17 Urea nitrogen may
additionally be elevated due to many other factors, including renal failure, drug-induced
renal failure (i.e. Nonsteroidal anti-inflammatory, Tetracycline drugs, Corticosteroids),
stress, gastrointestinal bleeding, shock, and volume depletion.21 Other known etiologies
of elevated BUN include catabolic states and high-protein diets.
Serum Creatinine
Creatinine is produced by the breakdown of muscle creatinine. It is thought that
creatinine clearance declines by 1mL/minute per year as a person ages. In an adult male,
serum creatinine that is greater than 1.2 mL/dL is considered above the standard normal
level.21 Increasing serum creatinine has been correlated in previous studies with
advancing renal failure due to obstruction and use of certain types of medications
(Nonsteroidal anti-inflammatory, Aminoglycosides). Decreased serum creatinine has
been linked to decreased muscle mass and severe liver disease (seen in patients with
advancing prostate cancer).35
Proteinuria
Elevated levels of protein in the urine of a male patient should warrant a complete
genitourinary workup. The condition has 12 known potential etiologies in the differential
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diagnosis, of which malignancy of the lower urinary tract (to include prostate cancer) is
among them.21 Elevated urine protein is most commonly seen in prostate cancer patients
with systemic disease spread and has not been evaluated as it relates to preclinical, early
prostate cancer.
Prothrombin (PT)/Partial thrombin time (aPTT)
Disseminated intravascular coagulation (DIC) disorder has been reported as a
complication of prostate cancer for many decades.74 Disseminated intravascular
coagulation disorder is an activation of the coagulation cascade, which if untreated can
lead to multiple blood clots in the bodies blood vessels, as well as severe bleeding and
organ failure.75 Originally, a succession of case series reported patients with advanced
prostate cancer demonstrated lower levels of serum fibrinogen (when compared to
patients without prostate cancer).76 It was hypothesized that the prostate tumor expressed
a fibrinlytic tissue factor that was the underlying etiology of the DIC disorder.75
However, later epidemiologic studies pointed to systemic coagulation irregularities as the
primary culprit.76 The exact incidence of DIC in PC patients has been estimated at 10 to
15 percent, with more studies reporting rates closer to 5 percent .75 Most published
studies surrounding DIC and prostate cancer have evaluated DIC incidence in patients
with localized disease, or in patients post transrectal prostate biopsy. The incidence and
prevalence of DIC with advancing stage and grade has not been thoroughly evaluated. In
addition, there is a lack of published research on changes (if any) of Prothrombin Time
(PT) and Partial Thromboplastin Time (aPTT) values in the presence of prostate cancer.
Both PT and aPTT are used to evaluate the coagulation system, with increasing levels of
PTT an independent predictor of DIC.75
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Disseminated intravascular coagulation is a systemic disorder that is seen as a
complication of prostate cancer. The exact rate of occurrence in PC is unknown, and the
changes seen in hematologic tests as a result of DIC have not been evaluated as a
predictive tool for advancing stage and grade of prostate cancer.
Epidemiologic Risk Factors for Prostate Cancer
Ethnicity
Prostate cancer incidence and mortality rates are disproportionately higher in
African-American males than white males in the United States.44 African-American men
have incidence rates that are two times higher than white males, and their mortality rates
are 120 percent higher.44 African-American men have a risk rate 1.12 times higher than
white men for developing prostate cancer in their lifetime.49 Many reasons have been
hypothesized as to why this is so, with a preponderance of prior research pointing
towards delay in diagnosis as a primary factor. Diagnoses of prostate cancer is made at
later stages in African-American men than white men.45 Data on prostate cancer
incidence stratified on ethnicity from the National Cancer Institutes’ SEER program
(Surveillance, Epidemiology, and end results) demonstrates the disparities between
ethnicities well. African-American men have the highest rates of prostate cancer
incidence, mortality, and aggressive spread of all ethnic groups in the United States.48
Age adjusted incidence rates for African–American men have risen faster than other
ethnic groups. For example, from 1973 to 1993 African–American rates have risen from
62.8 per 100,000 to 270 per 100,000.48 Conversely, white male incidence rates have
increased from 62.5 per 100,000 to 164 per 100,000 in 1993.48 The increased incidence of
prostate cancer overall has been attributed to better screening techniques, as well as
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increased clinician and public awareness.47 However, the improved screening techniques
and increased awareness does not account for the difference between ethnic prostate
cancer rates. African-American men have shown a significance difference in prostate
cancer mortality rates as well. From 1973-1993, the SEER data demonstrates an increase
in death secondary to PC for African-American men from 39.5 per 100,000 to 56 per
100,000.48 In comparison, white males had an increase of 20.3 to 24.3 in the same time
period.48
The underlying etiology of these differences has proven difficult to discern. It is
believed that African-American in general have delayed medical care when compared to
whites, but it is believed that this care deferment difference does not completely account
for the ethnic differences that exist in prostate cancer incidence and mortality.17
No clear genetic link has been demonstrated to account for the differences in
prostate cancer rates between white and African-American men. A study looking at
changes of different chromosomal regions in prostatectomy samples noted changes in the
8p chromosome were seen more frequently in the samples from African-American
patients than samples obtained from white patients.52 The samples were matched on stage
and grade and follow-up studies are currently ongoing.
Prostate cancer has been shown in previous studies to be a hormonally dependent
condition.4, 108, 110, 113, 115 Decreasing circulating testosterone in men with prostate cancer
(orchiectomy vs. medication) has been shown to be an effective PC treatment.
Researchers have hypothesized that there could be a link between increased levels of
hormones and subsequent prostate cancer development. Various epidemiological studies
have failed to demonstrate an association between androgen levels and PC.56, 115
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Furthermore, African American adult men have not shown any difference in their
hormone levels when compared to other ethnicities. Studies looking at levels of
circulating hormones in utero and adolescence have not been thoroughly evaluated,
although one published study did demonstrate increased levels in utero for AfricanAmerican men.56 The relationship between increased hormones in utero and the latter
development of PC has not been fully evaluated.
Foods and other environmental factors have been hypothesized as possible
exposures than could explain the difference in prostate cancer rates between ethnicities. It
has been previously demonstrated that consumption of dairy products, saturated fats,
proteins, soy, and lycopene affects (both increasing or decreasing) the probability of
developing cancer of many different systems, including the gastro-intestinal, urinary, and
genital tract.99 Although complex, diets high in animal saturated fat have been linked to
increasing risks of prostate cancer.53 In a study that evaluated diet, exercise, and body
size with the development of prostate cancer demonstrated for all ethnicities (including
Asian), the risk of PC increased as animal fat intake also increased.54 In addition, prior
studies on food consumption tendencies among different ethnicities points towards
increased fat consumption among African Americans when compared to whites.55
However, a clear causal pathway between increased animal fat consumption in African
American men and increased rates of PC has not been demonstrated, and with the
possibility of significant confounding and misclassification, the likelihood of uncovering
such an association in the future is unlikely.
Age
The incidence and prevalence of prostate cancer increases as men become older.10
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The median age at diagnosis for PC is 71 years old.105 The mortality rates associated with
PC are not as high as incidence and prevalence rates because of the many competing
causes of death seen with the elderly. The leading cause of death in men aged 55 years or
higher is heart disease.2 Prostate cancer is the fifth leading cause of death in men.10 In
2001, 31 percent of male cancer deaths are secondary to lung cancer with only 11 percent
due to prostate cancer.105 Approximately 35 percent of men aged 60-69 years old have
PC, compared to an autopsy prevalence of 70 percent in men aged 80-89 years old.9 In
developed countries, over 80 percent of PC cases occur in men 65 years old or older.105
The lifetime risk of developing PC is over 3 times greater for a men living in developed
countries compared to third-world countries. This discrepancy is attributed to greater life
expectancy and diagnosis at earlier disease states.102, 115
Family History
A positive family history of prostate cancer is a strong risk factor for future
prostate cancer development.10 Over the last decade; genetic researchers have been
working towards identifying the specific genes associated with hereditary PC. The goal is
to create tests that can be used to identify men at high risk for future PC development.
The exact gene that is responsible for hereditary PC has not been identified, but a positive
family history does increase risk. This risk depends on certain factors, including the
number of first degree relatives afflicted with PC and the age at diagnosis. 10, 106, 115
In a 1999 prospective study at the John Hopkins Hospital, (which evaluated the
value of screening individuals at known increased risk for prostate cancer development),
the researchers evaluated over 10,000 participants and found that men in families with
two or more cases of PC had 11 times the risk of developing prostate cancer at 60 years
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of age and 5 times the risk at 70 years of age when compared to a man without a family
history.106 In addition, this study used Cox regression techniques to control for other risk
factors and found that men with brothers who had had PC increased their risk greater than
that of having a father or uncle with the disease.106
Many studies have been performed to evaluate whether PC in a patient with a
positive family history is different than PC in a patient without a family history of the
condition. Factors including clinical stage at presentation, preoperative PSA level,
prostate size, prostate weight, and number of cancer foci present were all evaluated.
There were no significant differences between the two PC groups in any of the above
factors.107, 108, 109
Geographic Location and Diet
Exogenous factors are believed to influence PC incidence. For example, prostate
cancer rates differ based on geographic location. The United States and Western Europe
have historically had the highest rates of PC incidence, prevalence, and mortality in the
world. Conversely, the Asian continent has had the lowest known risk of prostate
cancer.97 In an ecologic study looking at cancer incidence rates between continents, the
age standardized annual cumulative incidence rates (CIR) for Asian men were reported at
1 per 100,000. In comparison, U.S. African American men PC CIR were at 82 per
100,000, with Caucasian males at 62 per 100,000, respectively.97
Additionally evidence that supports exogenous factors influencing PC
development is seen through migratory studies that have looked at PC trends in Asian
men living in Asia, the United States, and Europe. The incidence of PC is higher in men
who migrate from countries of low risk for PC development to countries of higher
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risk.100, 101 Asian men living in the U.S. or Europe had higher rates of PC incidence than
their ancestors still residing in Asia.100, 101 When the study controlled for differences in
the detection time between the different regions, statistically significant differences in PC
incidence remained.101
Correlational data also suggests alteration of PC risk can be realized by
modification of dietary practices. Where as some types of foods seem to increase PC risk
(red meat, dairy products, and animal fat), others appear to offer protective benefits
(lycopene, selenium, and Vitamin E).
Prior published ecological studies have demonstrated strong correlations between
PC development and consumption of dairy products, red meat, and animal fat. The
positive correlation appears strongest with dairy products, with one study demonstrating a
correlation of .69.102, 117, 118 Ecologic fallacy and confounding are possible explanations,
but additional case-control and cohort studies seem to support this relationship, albeit not
as strong.107, 109, 119, 120 Two hypothesized explanations of the relationship between PC
and dairy products centers on the fat content and the high bio-availability of calcium in
milk. The calcium hypothesis has gained support from a 1997 prospective study that
evaluated dietary fat intake and PC risk. This study demonstrated that consuming
increased amounts of fat-free and skim milk carried an increased risk of PC
development.103
The ‘Western diet’ has also been evaluated as a PC risk factor. It has been
hypothesized that this diet (high intake of red meat, animal fat, dairy products, and
protein) results in increased energy consumption, which can lead to increased levels of
Testosterone, cell proliferation, and angiogenesis, with decreased cell differentiation and
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apoptosis.104 This combination would lead to increased prostate growth, PIN, PC, and
faster disease progression. However, epidemiologic studies have varied in their results.
Where some studies have demonstrated increased PC risk, many others have reported no
increased associated risk. 107, 109, 118, 119
Although as a group, fruits and vegetables have not been associated with
decreased PC risk profiles, certain vegetables have been supported as potentially
protective. Lycopene has been studied since the 1980s for its affect on PC risk. Many of
the studies demonstrated reduced risks associated with high intake of Lycopene; however
they were not statistically significant. One 1995 U.S. study, which evaluated 773
subjects, demonstrated a statistically significant risk reduction (RR-0.65, 95 percent CI0.44-0.95) when consuming greater than 10 dietary tomato-based products per week
(compared to less than 1.5 servings). Although the data remains controversial, the
increased consumption of tomato-based products (as well as fruits and vegetables) is
recommended for cancer risk reduction and better overall general health.
Vasectomy
Prior epidemiologic studies looking at a possible link between PC and undergoing
a vasectomy have failed to demonstrate consistent evidence of a causal association.111, 112
This potential association has been under review for approximately twenty years.
Although a number of studies have suggested there are increased risks of PC
development associated with vasectomy surgery, many other studies have failed to
demonstrate similar outcomes.113, 114, 115
In a 1992 retrospective cohort study looking at the incidence rates of cardiac
arrest, testicular cancer, and prostate cancer in men who had underwent a vasectomy; no
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evidence of increased PC risk was identified. Over 13,000 men who had a vasectomy
were compared to 26,000 men who were hospitalized for elective operations,
appendicitis, or injuries. The study reported a relative risk of 1.0, but noted longer periods
of follow-up may be needed to study vasectomy effects on PC definitively.117
An additional study from 1996 conducted in Puget Sound evaluated 175 men
(who were status post vasectomy and recently diagnosed with histologically confirmed
PC) with 258 controls. These controls were randomly selected from the general
membership of the Puget Sound insurance group health plan. Conditional logistic
regression analysis yielded an odds ratio for PC associated with vasectomy of 0.86
percent (95 % confidence interval 0.57-1.32).112
Skepticism remains over this suspected relationship, centering around two
primary factors; biological plausibility and selection bias.111 The biological basis that
attempts to explain the link between vasectomy surgery and increased PC risk has been
questioned and remains speculative.113, 116 It has been shown that vasectomies result in a
complete decrease of sperm, which in turn results in a decrease of total percent
concentrations of prostate secretion and seminal vesicle hormones, while simultaneously
increasing the level of sperm-antibodies.116 It is unknown if (and how) any of these
biological changes results in increased PC development.116
In addition, selection bias remains a potential explanation for the previously
demonstrated increased risk. Most vasectomies are performed by urologists, and most PC
are diagnosed by urologists, therefore men who have undergone vasectomies are more
likely to have their PC diagnosed.113
Additional research is needed in this area, specifically prospective cohort studies
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and clinical trials. Moreover, previous studies have shown potentially increased risk in
various sub-populations, therefore focus on those men at potentially increased risk prior
to the vasectomy should deserve particular acute focus.
Alcohol
Alcohol consumption effect hormones by transiently depressing circulating
testosterone levels (in men) and increasing estrogen levels (in women).119 Alcoholic
cirrhosis has also been shown to depress circulating testosterone levels.120 There has been
significant interest in a possible link between alcohol use and PC development.121
Alcohol consumption is a prevalent life-style activity and is modifiable, therefore
the identification of a causal relationship with PC would have a significant impact on
public health.119 Prospective and retrospective reviews have been performed on the
potential relationship between alcohol consumption and PC and has found limited
evidence to support a causal association.119 There has been greater than 30 studies
investigating this potential link over the last 30 years.119
A 1996 study looking at PC risks in relation to alcohol intake in U.S. AfricanAmericans and whites demonstrated a significant association (RR 1.8, 95% CI 1.1-3.0)
with high grade PC and heavy alcohol intake (greater than 57 drinks per week). When the
PC outcome was evaluated as a binary outcome, the relative risk was not significantly
increased. Moreover, follow-up studies have not found similar results.118
A European study, looking at the influence alcohol plays on PC, found a gradient
association between total grams of alcohol consumption and PC development in Swedish
men. However, their results were not statistically significant, thus the apparent
relationship could have occurred by chance.125
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In a review of all previously published literature that summarized issues of
causation, no compelling evidence of a causal link between low-to-moderate alcohol use
and PC was observed.119 The authors recommended targeted research focused on select
subsets of men including heavy alcohol consumers. In addition, they recommended
population prospective studies, as well as increased attention on genetic markers of
patients with familial risks.119
Vitamin A
Prior research on cancer incidence suggests increased consumption of vitamin A
can be a protective dietary practice.125 However research on the association between
vitamin A and PC has hinted that a more complex relationship may exist. There have
been published studies that have attributed both protective and causal effects associated
with increased vitamin A intake on PC developement.125-129
The National Health and Nutritional Examination Survey I Epidemiologic
Follow-up Study followed over 2,440 men (> 50 years old) for an average of 10 years
and found mean levels of serum vitamin A were lower in men who developed PC when
compared to men who did not develop PC.126 These results were statistically significant
and were evaluated as both a continuous and ordinal variable.126 After adjusting for age
and ethnicity, the researchers found that men in the lowest quartile of vitamin A intake
had a RR of 2.2 (95% CI 1.1-4.3) when compared to men in the highest quartile. The
increased risk of PC development did not weaken with increasing time between serum
draw and diagnosis.126 In addition; similar protective findings were also reported between
vitamin A intake and PC in a case-control study published in 1988.127
In 1989, dietary and lifestyle characteristics of approximately 14,000 Seventh-day
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Adventist men were obtained for comparison with subsequent PC development.128 Each
study subject completed detailed questionnaires on a variety of lifestyle factors, including
information on foods known to be high in vitamin A. Consumption information was
obtained on the following specific foods: green salads, citrus fruits, and tomatoes.128 The
researchers utilized Cox proportional hazards regression models for statistical analysis
and found men that consumed foods that are known to contain increased levels of vitamin
A had a decreased risk of PC development (See Table 3 below).
Fruit and Vegetable
Consumed

Relative Risk

95% CI

Green Salad (>= 1x/Day)
0.68
(0.44-1.05)
Fresh Citrus fruit (>=
0.53
(0.34-0.86)
5x/Week)
Tomatoes (>= 5x/Week)
0.57
(0.35-0.93)
Table 3. Age-Adjusted Relative Risk for PC by Fruit and Vegetable Consumption
(Mills, Beeson, Phillips, and Fraser, 1989).
One study that demonstrated conflicting findings was a retrospective, casecontrol study, which was performed in Hawaii on 1,351 men (452 PC positive, 899
population controls). All men within the study provided detailed dietary histories between
the years of 1977-1983. The men were stratified on age (< 70 or >= 70 years), and
controlling for differences in ethnicity was performed.126 The researchers found that men
70 years or older strata, who were in the highest quartile of vitamin A consumption
group, had a statistically significant odds ratio of 2 when compared to the lowest
consumption group.126
Two additional published studies demonstrated larger risks of PC development
with increased consumption of vitamin A. A study by Graham, et al., found the relative
risk of PC increased in a gradient fashion as vitamin A increased. This trend was more
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apparent in men 70 years or older.129 Hershmat, et al., described a similar relationship in
a case-control study that was published in 1985, although the odds of PC development
was strongest in younger men (less than 50 years of age).130
Many explanations have been hypothesized as to these conflicting results. The
differences may be a result of inherent difficulties of capturing data on diet, as well as
separating vitamin A from other carotenoid and retinoid compounds. Additionally, the
majority of the retrospective analyses have lacked large case numbers and as a result the
powers of these studies remain in question.
Other Micronutrients
The antioxidant, vitamin E, has been evaluated as a possible protective agent in
cancer genesis due to its reported anti-cancer properties.999 It is previously been
suggested that vitamin E may impede the development of cancer by inducing apoptosis in
cells with altered or damaged DNA.105 There is limited epidemiologic studies on the
possible relationship between vitamin E and PC, however.
A randomized prospective study published in 1998 demonstrated a protective
effect with vitamin E use. In the study, men were either randomly assigned to receive
either a placebo or vitamin E supplementation in their diets. The men that received the
vitamin E had a reduction in their PC incidence of greater than 30 percent, and the
mortality second to PC decreased by greater than 40 percent.120 In a more recent
evaluation of the potential protective effects of vitamin E, 1,896 physicians were tracked
prospectively in the Health Professionals Follow-up study. Augmentation of diets with
vitamin E did not result in a lowering of the risk of PC development. This particular
study enhanced the accuracy of the vitamin E measurement by documenting intake twice
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per year, and also had increased power when compared to the previous (1998) study.121
However, a protective effect was seen after stratifying on smoking status and
looking only at the aggressive PC cases. The ex-smokers had a relative risk of 0.51 (95%
CI 0.26-0.98) when compared to never smokers. The authors recommended further study
of vitamin E, in particular the potential effect modifying relationship seen with smokers.
Prospective studies exploring this relationship are ongoing.
Vitamin D has been evaluated for over 10 years to discern the exact role it plays
in prostate cancer genesis. Molecular studies have demonstrated that vitamin D receptors
are present on prostate epithelial cells and PC cell lines.131 These receptors are thought to
increase the expression of androgen receptors and PSA androgen-regulated genes.
A 1990 study that evaluated vitamin D as a risk factor for PC development
reported that patients with low serum vitamin D levels had a significant relationship with
ethnicity, age, and geographic location, frequently cited PC risk factors. A second
epidemiological study demonstrated that decreased serum vitamin D levels (Ca2 less than
8mg/dl) was associated with increased risk of high-grade tumors and advanced stage
disease.132
Clinical trials of vitamin D and its analogs are underway currently and although
hypercalcemia was a frequent complication, it is believed that these compounds can
reduce any PC prompting activity currently seen with varying vitamin D serum levels.
Obesity
Previously published case-control studies suggested that obesity increases the risk
of PC development.99, 107, 109, 110 Ecological studies have demonstrated strong correlations
between obesity and increased risk of PC development.99-, 107, 109 However, given certain
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methodological issues, this relationship has been questioned. In many studies, the
utilization of only height and weight was utilized to assess body mass.107 Moreover,
consistency between retrospective and prospective studies have been lacking. As a result,
it is unclear if obesity is a causal exposure for PC development.
The first study that published findings suggestive of a causal association between
increasing body mass and PC was a hospital based case-control study out of Northern
Italy.110 The researchers reported that increased PC risks existed in obese men (when
compared to men of the expected body mass). Limitations of this study included the
utilization of hospital based controls, and determining body mass strictly on the basis of
height and weight.110
To correct for this limitation, a prospective study published in 1988 evaluated the
influence that body mass had on PC development with the utilization of several body
measurements.52 The authors initiated a more detailed assessment of the subjects to
delineate increased body mass secondary to muscle verses adipose tissue. They calculated
Incidence Density Ratios (IDR) on 7,820 men, comparing a multitude of different body
measurements. The researchers reported that the risk of PC was not significantly related
to BMI, skinfold thickness, height, or leg length.52 They did note that the RR was
significantly increased with girth in the upper arm and weight in kilograms, although this
relationship did not demonstrate a linear trend.52 The authors concluded that their results
were preliminary and that it appears the risk of PC increases with increasing muscle mass
and not necessarily with adipose tissue weight gain.52
In a study published in 1971, Wynder et al. retrospectively evaluated 1,050
patients to better determine the epidemiologic factors of prostate cancer and review
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certain factors believed to be associated with PC development.51 The review looked at
300 subjects who were diagnosed with PC, 400 controls, and the charts of 350 additional
patients who had PC.51 Two factors that were evaluated closely included weight and
height. The authors found no significant difference in the height and weight of the PC
subjects when compared to the controls. In fact, a higher percentage of control patients
were overweight than the PC patients.51
In addition, a 1984 prospective study noted increased PC risks for overweight
men.59 The study evaluated a cohort of 6,763 white male Seventh-day Adventists who
had completed a dietary questionnaire in 1960.107 They were followed-up to assess the
effects obesity played on the risk of fatal PC development. They authors reported that
men who were overweight had a significant RR of 2.4 (95% CI 1.3-4.5) for fatal PC
development, when compared to men within the referent group.107 Although this study
provides compelling statistics, the study utilized basic measures of diet, as well as basic
measures of body mass. In addition, since the studies endpoint was fatal PC, it is unclear
whether the disparities in types of food intake resulted in increased death secondary to the
PC or a competing cause of death. In addition, the issue of inaccurate cause of death
determination on the death certificates cannot be discounted.
Although there appears to be some evidence of a causal relationship between
obesity and PC, difficulties with methodological issues (and a lack of prospective studies)
has hampered the understanding of this complex relationship. As a result, any assertion
that obesity can increase a subject’s risk of PC development is purely speculative.
Circulating Testosterone
Testosterone is an essential androgen hormone that is vital for the healthy, normal
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development of male reproductive organs. It is believed to be responsible for
spermatogenesis and the regulation of gonadotropic secretion.31 In addition; testosterone
is a common treatment for hypogonadism, and is used as a palliative therapy for breast
cancer.31
For decades, many researchers and clinicians have hypothesized that increased
levels of circulating testosterone is a risk factor for PC development. However, the
plausibility of this causal relationship has been questioned, given that PC is dependent on
continued availability of androgens, and androgen levels decrease as a man ages.109 The
decreasement of circulating testosterone has been a PC treatment strategy for many
years.108 The complete understanding of this complex relationship has proven to achieve.
Difficulties in evaluating testosterone levels and methodological limitations in previous
studies designs has been cited as limiting factos.109 For instance, many of the published
studies have utilized blood samples that were taken after the diagnosis of PC, thus
concerns over the temporality of the relationship exist. In addition, many of the previous
studies have limited sample size, or non-representative control groups.108
However, a study out of Canada evaluated the relationship between Serum
testosterone and dihydrotestosterone with PC on 75 (33 PC patients, 42 controls)
otherwise healthy men. The noted the mean value of serum testosterone for the control
group was 16.74 (95%CI 17.5, 15.98), while the PC patients was 20.94 (95%CI 22.42,
19.46). The results were statistically significant, however the researchers stated that the
wide range in values seen in the PC patients limits the practical value of the biomarker,
and further study by a prospective approach would be necessary.
In 1996 a prospective study was performed, investigating whether plasma
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testosterone and sex hormone-binding globulin levels in men were related to the
subsequent development of PC.107 The researchers utilized a prospective, nested casecontrol approach, looking at the participants of the Physicians’ Health Study who
provided blood samples for future evaluation. There were 222 participants who
subsequently developed PC after the study began. Three hundred-ninety controls were
matched on age, smoking status, and length of follow-up. Logistical regression modeling
was used to determine the Odds Ratio specifying the risk associated with increasing
hormone levels. High levels of circulating testosterone demonstrated a association with
PC as levels of plasma testosterone increased.107 For increasing quartiles of plasma
testosterone, the OR were as follows: 1.00, 1.41, 1.98, and 2.60.107 The confidence
intervals were statistically significant, and the researchers concluded that high levels of
circulating testosterone were likely associated with PC.
History of STD and Other Sexual/Reproductive Factors
Age at first sexual intercourse, intercourse frequency, history of Sexual
Transmitted Diseases (STD), and the number of sexual partners have all be evaluated as
potential risk factors for the subsequent development of PC. It has been hypothesized that
PC may be caused by the transmission by an infectious agent through sexual activity.112
However a cohort study of cancer mortality demonstrated an excess of PC deaths in
Catholic priests, which points away from an STD etiology.113 The results of the
subsequent follow-up studies have failed to demonstrate a clear causal pathway.
The most thorough evaluation of these potential causal exposures was performed
in California in the late 1970s. This population-based, case-control study was performed
on 221 men who were identified by the Los Angeles county cancer surveillance program
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as having histologically diagnosed prostate adenocarcinoma. Cases were restricted to
white, non-Spanish sir names, and each case was assigned a similar neighborhood
control. Both the cases and control were interviewed over the phone using a structured
format by a single trained interviewer. The researchers reported that the risk of PC
development were higher in men with earlier age at first sexual intercourse (age <17 vs.
21+, RR = 2.3, 95% CI 1.3-4.0), but there was no association with the number of sexual
partners or the frequency of sexual intercourse.112 Moreover, there was not a significant
relationship with STD history, although the small number of cases limits the
interpretation of the results.
Socio Economic Status
The relationship between socio economic status (SES) and PC incidence has been
evaluated since the 1950s. At that time, literature suggested that the increased PC
incidence seen in African-American men could be related to lower SES.107 However,
follow-up studies that have evaluated education, income, and residence zip code (with PC
development), failed to demonstrate consistent evidence to support this hypothesis. In a
1971 study of PC modifiable risk factors, the relationship between education attainment
and PC development was analyzed separately for both Caucasian and African-American
men.108 For Caucasian men, there was no significant difference between rates of PC
incidence and the different education categories (stratified as ‘no school attendance’;
‘grammar school’; ‘high school’; and ‘college’). African-American men who had
attended grammar school or less had a 14 % increased risk of PC development. However,
due to small sample size, the results were not statistically significant.
In 1972, a study in California again revisited socio economic status and its
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relationship to PC incidence and mortality. This case-control study compared PC
incidence data from the Alameda county cancer registry and death certificates data with
the average income for the Alameda residence zip codes. The researchers found that after
stratifying on ethnicity, African-American men maintained their increased incidence rates
(compared to Caucasian men), despite the increased education. However, the study did
not report the statistical significance of their findings.
Occupational Studies
There is mounting evidence that suggests there exists an inverse relationship
between certain types of cancers and occupational activity.123 In particular, diverse
populations have been studied in relation to job-related activity and their risk of colon
cancer, and there is a consistent association between occupational physical activity level,
recreational physical activity level, and colon cancer risk.123 The specific relative risks
has varied between the studies, with one study demonstrating no apparent association,
while other epidemiological studies report risks between 20-100 percent, respectively.122
In a 1991 Missouri case-control study, the odds of white men being diagnosed
with prostate cancer were increased if they had low or moderate activity levels at work.122
This study was initiated to evaluate cancers in relation to occupational activities. The OR
of a white male worker developing PC was 1.1 (95% CI 1.0-1.3) for men with moderate
activity, and 1.5 (95% CI 1.2-1.8) for men with low activity levels (compared to the
reference group; high activity).122 The odds ratio for low activity level was statistically
significant, and the researchers controlled for age and smoking status. The authors
concluded that their results should be considered preliminary and require confirmation
with other studies.122
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In a study published in 1987, which looked at the relationship between
occupational activity and the incidence of cancer (including PC), it was reported that
longshoreman with decreased occupational activity levels had increased odds of PC
development (when compared to longshoremen with increased activity levels).124 This
study was performed in San Francisco, California, and did have certain limitations. These
limitations included a lack of controlling for Social Economic Status (SES), and had a
vague surrogate marker for physical activity.124
The biological mechanism that links physical activity levels and PC development
remains unclear. Researchers and clinicians have hypothesized that the relationship may
be bound by a decrease in the cancer growth promotion factors as a result of the physical
exertion.122 This may be so, but it has been proven difficult to discern exactly how much
physical activity is required, and for what duration, for the protective effects to be
realized. A better measure of job related activity, randomized clinical trials, and
prospective studies are required to answer this question with more clarity.
Tobacco
The use of tobacco products (specifically cigarette smoking) has been evaluated
as an exposure that increases the risk of developing prostate cancer. However, the results
of previous studies evaluating this relationship have been unclear. A slightly increased
risk has been identified; however it has not been consistently demonstrated and
researchers are unsure if this relationship was actually due to the biological effect of the
tobacco smoking, or secondary to delayed diagnosis and treatment.94
Different pathways have been hypothesized on how tobacco could induce PC.
One revolves around the tobacco use prompting a more ‘aggressive’ phenotype that
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progressives more quickly and is more fatal. A second hypothesized pathway centers on
the concept of ‘hormone alteration’, either resulting in the hormones prompting cancer
growth, or turning off the tumor impeding genes.95
Conclusion/Assessment of the Literature
There exists a gap in the literature addressing PSA as a prostate cancer screening
tool. Earlier PSA research by Catalona, the U.S. Preventive Task Force, (and more recent
work by Thompson, Carter, the PLCO, and others) have been critical in improving our
ability to identify prostate cancer at earlier disease stages. However, there is continued
debate on whether (or not) PSA remains the best currently available tool for the detection
of pre-clinical PC. This debate is likely to continue until the results of the PLCO trial are
released (tentatively scheduled for 2014). There seems to be little debate over the
limitations PSA possesses as a PC screening tool. Undoubtedly, a strength to prior peerreviewed published literature has been the consistent demonstration that, since the
inception of PC screening on a national level, the utilization of a single PSA draw (with
or without DRE) as the prompting factor for prostate biopsy referral has resulted in
millions of unnecessary (non-risk free) prostate biopsies.5, 22 An overt weakness of the
prior published studies has been the lack of easy to implement solutions to this complex
problem.
How can PC screening be improved upon? Despite a wealth of published
literature that has evaluated PSA and argued against its use as a PC screening tool, PSA
remains the mainstay for clinicians for PC screening. Thus, the focus must be on
augmenting PSA, not replacing it all together. Prior attempts at improving PC screening
have focused on replacing PSA with a new test. Tools such as PSA velocity, PSA
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density, Free/Total PSA ratio, and newer assays have all shown promise in studies for
improving PC screening results, but difficult implementation and a lack of universal
acceptance among clinicians have hindered their incorporation into daily clinical
practice.7, 23, 26, 27, 40, 41, 41, 86
Has researchers and clinicians made the most of all available information
when evaluating a patient for prostate cancer? Routinely ordered lab panels (complete
blood counts (CBC), basic metabolic panels (BMP), and urinalysis (UA)); all contain
biomarkers that change in value when diseases associated with prostate cancer are
present. Yet these biomarkers have been in essence ‘ignored’ when evaluating a patient
for PC.
Many previous studies have accurately described PSA elevations as ‘specific to a
condition of the prostate’. However, in what must be considered a weakness of the
literature, there has been a lack of clarity in describing that the aforementioned PSA
elevations are not specific to prostate cancer. In what may hold the key to improving the
overall yield of PC screening, evaluating changes in certain laboratory biomarkers values
that (in the presence of an elevated PSA) are associated with diseases that are a product
(directly or indirectly) of PC spread may provide a wealth of important information that
can improve of ability to accurately predict PC presence in patients undergoing PC
screening.
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Chapter III -Methods
The overall goal of this study is to improve the efficiency of prostate cancer
screening through the development of a clinical decision rule that is based on an elevated
PSA and a predictive set of clinical biomarkers. The study is a cross-sectional study,
evaluating men from the James A. Haley VA hospital from January 1, 1998 through April
15, 2005. The men are between 40-90 years of age, prior military servicemen, who utilize
the Tampa VA medical network for at least some of their health care needs. All men have
all undergone prostate biopsy. The subjects are classified into one of four ‘histology’
groups. The cases consist of biopsy confirmed prostate cancer. There are 3 control
groups: (1) biopsy confirmed Prostatic Interstitial Neoplasm (PIN), (2) biopsy confirmed
Benign Prostatic Hypertrophy (BPH), or (3) biopsy confirmed prostatitis, to answer three
primary questions of interest (see below).
1 - Aims/Hypothesis
Aim 1: The first aim is to identify biomarkers that are both related to prostate
cancer and have the capability of improving the efficiency of PC screening. Within the
biopsied groups of men, evaluation of routinely ordered laboratory biomarkers
(hematologic, serologic, and urologic) will be performed to assess for statistically
significant relationships between the biomarkers and disease status. It is known that PSA
values can be elevated due to many prostate conditions, however it is believed to be
unlikely that the non-cancerous conditions that elevate PSA would also cause changes to
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other body systems (represented by the lab biomarkers). In prior published research,
advanced prostate cancer has been indisputably identified as a cause for such laboratory
changes.34 In a 1997 study; anemia was a frequent complication of advanced prostate
cancer. The two primary types of anemias identified with PC are Iron Deficiency Anemia
(a subset of microcytic anemia), and anemia of chronic disease (either
normocytic/microcytic anemia). The etiology of anemia in prostate cancer patients is due
to the cancer itself, the therapy for the cancer, or unrelated conditions.34 Currently; there
is a paucity of documented research assessing the impact of cancer related anemias on
cancer screening.32
Hypothesis 1: Among VA patients who have undergone prostate biopsies secondary
to a PSA value of >4ng/dL, specified lab biomarkers* among cases of prostate
cancer will differ significantly from those among VA patients without prostate
cancer.
Aim 2: Upon completion of the above aim, sets of orthogonal biomarkers will be
developed to determine which can best predict the presence of prostate cancer. These
potential screening sets will be compared to the current screening tool (PSA only), to
evaluate for improved effectiveness in prostate cancer detection. The inclusion of
additional predictors offers potential for decreasing false positive tests, resulting in
increased specificity, predictive values, and better overall validity.
Hypothesis 2: Among VA patients who have undergone prostate biopsies secondary
to a PSA value of >4ng/dL, the addition of specified lab biomarkers* will improve
the effectiveness of predicting the presence of prostate cancer when compared to
PSA alone.
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An essential goal of this study is to increase the identification of PC that has the
potential to threaten life. This PC has not yet afflicted serious morbidity and mortality,
but will if untreated. Therefore, perhaps the most important cases of prostate cancer to
identify through screening are stage A and B which have aggressive grade scores.
Many stage A (low grade), indolent prostate cancers are unlikely to become
clinically evident, and their identification through PC screening is not of paramount
importance.10, 16 Prostate cancers that contain aggressive properties would (theoretically)
demonstrate evidence of both prostate activity (verified through elevated PSA), and
systemic evidence of cancer (verified through lab biomarker changes). It has been
previously established that PSA values can be elevated due to a multitude of prostate
conditions.41, 87 However, it is considered unlikely that non-cancerous prostate conditions
will cause changes to other body systems (represented by the lab biomarkers). Moreover,
indolent cancers are believed to be unlikely to cause an identifiable biological change,
and the PC that has overtly traversed the prostates borders will typically demonstrate
clinical symptoms (urinary obstruction, bone pain, weight loss, etc.), thus more likely to
be diagnosed in the clinical setting.
Aim 3: The third aim of this study is to assess for a dose-response relationship
between specified lab biomarkers (surrogates for extra-prostatic disease development)
and the progression of prostate cancer. If present, this parallel progression will
demonstrate the presence of a gradient between prostate cancer and systemic disease.
Hypothesis 3: Among VA cases of histologically confirmed prostate cancer, there
exists a gradient between specified lab biomarkers* and increasing stage of prostate
cancer.
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2 - Participant Description
Participants are men who have undergone prostate biopsy within the VA
Healthcare networks located in Tampa, Florida. The demographic characteristics of the
population under study are as follows: The James A. Haley VA group are primarily
Caucasian middle-aged veterans (mean=68 y/o, SD=12) with an education attainment
level of at least four years of high school, or some college attendance.37 When the
education of veterans is compared to that of non-veterans on a national level, significant
differences exist. For instance, 12 percent of veterans had not graduated from high
school, compared to 18 percent of non-veterans. Moreover, 65 percent of veterans have
completed high school or have attended 1 to 3 years of college, compared to 56 percent
of non-veterans. Lastly, when comparing the rates of completing 4 or more years of
college, non-veterans are more likely to have accomplished this feat (26 percent
compared to 23 percent).
Data suggest that upwards of 2.5 million individuals receive all or part of their
healthcare needs from the VA medical system.37 The Florida VA healthcare network
handles on average a total of 1,718,528 male patient encounters each year.37 This total
represents approximately 6 percent of all the male visits within the National VA system.
The following table (Table 4) stratifies these numbers by age specific groups:
State

Age 50-54

Age 55-59

Age 60-64

Age 65-69

Florida

155, 611

198, 258

147, 565

164,481

Table 4. Summary of age distributions: male patient visits (Florida VA, 2001). Data
Source: VA Department, National Survey of Veterans.
The VA and census data estimate that as of 30 September, 2004, approximately
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93,500 men in Hillsborough County (Tampa, Florida) are eligible to receive healthcare
services at the James Haley VA hospital. Additional demographic data reveal veterans
compare closely to their non-veteran counterparts on several measures of socioeconomic
status; including personal income, and health insurance coverage.38 However, users of
VA inpatient and outpatient care have less health insurance coverage than veterans in
general.38 Approximately 9 percent of all veterans were uninsured in 1993, compared to
21 percent of veterans who used their VA medical benefits. This holds true for veterans
under the age of 65, as 13 percent did not have health insurance, compared to 29 percent
of those veterans that used the VA healthcare system.38
Inclusion criteria:
1. All patients with a PSA value of 4ng/dL (or higher) with a history of prostate
biopsy (TURP and/or core biopsies and/or prostatectomy) dated between January 1, 1998
until April 15, 2005.
2. Additional laboratory data (obtained at the time of PSA sample):

Hematology:

Chemistry:

Urinalysis:

Red Blood Count (RBC)
Hemoglobin
Mean Corpuscular Volume
(MCV)
Platelet count
White blood count (WBC)
PT/aPTT

Albumin
Urea Nitrogen (BUN)
Creatinine
Bilirubin-Direct/Indirect
Lactate Dehydrogenase
Total Protein

Hematuria
Proteinuria

Table 5. Laboratory Biomarkers
3. Males age 40 to 95 at time of initial diagnosis of PC, PIN, BPH, or prostatitis.
Exclusion criteria:
1. History of prior genital urinary malignancy.
2. Individuals for whom pathology report states that the biopsy specimen is
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inadequate.
3 - Design
The design for this investigation is a cross-sectional study. The subjects are
classified into one of four ‘histology’ groups. The cases consist of biopsy confirmed
prostate cancer. The controls consist of 3 groups; biopsy confirmed PIN, BPH, or
prostatitis.
4 - Case Identification
A diagnosis of PC is based upon a set of standard procedures for both the clinical
decision making process and the biopsy of the prostate. Upon identification of an
elevated PSA lab test (with or without the identification of a prostate nodule during
physical examination or transrectal ultrasound), the patient undergoes a prostate biopsy
that is then sent to the pathology department for histological determination. For quality
control purposes, random case review is performed monthly by local VA pathologists,
and external quality control is assured by 10 percent random case review by pathologists
assigned to the Armed Forces Institute of Pathology, located in Washington, DC.
5 – Data Collection Methods
A case of prostate cancer is defined by prostate tissue that demonstrates cells of
adenocarcinoma on histologic evaluation.4 With that, identification of potential study
subjects was accomplished through utilizing the search option in the Anatomic Pathology
portion of VISTA (SNOMED finalized accession logs) to find all cases coded as 'prostate
disease' (SNOMED codes: 77220, 77103, 77102, 77101, 77110, 77105, 77350, 77230,
77210, 77300, 77200, 77240, 77104, 77100, 77000, 77900, 77250). The patient’s
identification number, date of the specimen, diagnosis text code, and accompanying
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narrative text description were captured through this VISTA search. The SNOMED
system (Systematized Nomenclature of Medicine) is a division of the College of
American Pathologists, and is the standard tool used by pathologists to create, share, and
retrieve pathology information.125 The SNOMED system is used by the James Haley VA
hospital for aggregating all pathology data. The collection of both the diagnosis text code
and accompanying text description was performed intentionally as a way to validate the
histologic diagnosis. For instance, if the diagnosis code was ‘adenocarcinoma of the
prostate’ (SNOMED code 77220); the corresponding narrative text description would
provide the same diagnosis. The goal of this initial search was to capture all prostate
related cases; hence the abundant amount of SNOMED codes used. At this point there
were 2,575 unique patient identifiers that could be potentially associated with prostate
cancer.
The James Haley VA electronic medical records (EMR) were then accessed for
all of the identified potential PC cases to validate the diagnosis (by identifying PC ICD-9
codes or ‘PC’ stated as the assessment in the narrative dictation) and capture additional
data relevant to this study. Demographic data (age, ethnicity), laboratory biomarkers, and
any previous pathology results were captured through the review of surgical operative
reports, progress notes, medication logs, admitting summaries, and discharge dictation
summaries. This data was still grouped within the Vista system, and to development a
relational database, it was exported to the Microsoft Access system for further dataset
development. (A relational database is required to match data from different datasets for
each individual).
Upon satisfactory export of the above data, a relational database was created to
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link the different data sources. Multiple Access tables, queries, and forms were created.
In particular, the following 7 different tables were created in Access: histologic diagnosis
codes, narrative histologic dictation notes, inpatient diagnosis codes, demographics
(gender, age at biopsy, race, and ethnicity), laboratory biomarkers of interest, date of
biopsy (with age at biopsy), and ICD-9 codes for all previous diagnosis (within the JH
VA) recorded for each patient.
Access forms were then created as a tool to create new diagnosis categories. In
particular, new data elements were created that categorized each prostate biopsy as PC,
PIN, BPH, or prostatitis. Each biopsy diagnosis text code and accompanying text
descriptions were reviewed closely to reduce the probability of misclassification of the
study outcome (histologic evaluation of adequate prostate tissue).
A second Access form was created for capturing both the PC stage and Gleason
score for each patient with a histologic diagnosis of PC. The stage was categorized as
follows: stage A for non-palpable, prostate contained cancer; stage B for palpable,
prostate contained cancer; stage C for locally spread PC; and stage D for metastatic PC.
To determine the Gleason score, the two most prominent areas of PC activity (as
identified by the evaluating pathologist on histologic examination) were identified. Each
prominent area was given a score of 1-5, with 1 being well differentiated, and 5 being
poorly differentiated (implying a more aggressive appearance). The two scores are added
together, and this number was the recorded Gleason score for all subsequent analysis.
Upon establishing each subject’s new diagnosis category (which is to be used as
the primary outcome variable of this study) and Gleason score, these variables (as well as
laboratory and demographic data) were exported into Microsoft Excel for continued
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dataset development. After successful export of the above mentioned data into Microsoft
Excel, attention was given to determining the accurate ethnicity of each potential study
subject. Initially, both the race and ethnicity fields (within the histology text description
reports) were screened for ethnicity key words (e.g. Caucasian, African American, white,
black, etc.). However, more than 60 percent of these fields were left blank; therefore
addition capture techniques were employed.
For the 40 percent of the potential study population that did not have race or
ethnicity captured within the prostate biopsy histology text description reports, evaluation
of (EMR accessible) previous surgical operative reports, outpatient progress notes,
emergency room notes, admitting hospital summaries, and discharge dictation summaries
were reviewed, looking for any mention of race and or ethnicity. Screening for
commonly used medical short-hand information (e.g. 67 y/o aam; “67 year old African
American male”) was also performed, which ultimately left only 6.6 % (170/2575) of the
potential subjects with “unknown/refused” as their ethnicity designation.
For accurate determination of each subject’s age, the age was calculated by
subtracting the birth date from the date of prostate disease determination. The age of noncancer subjects was established by subtracting birth date from the date of histologic
evaluation.
To aggregate the specific laboratory biomarkers of interest in this study, an MS
Excel table was created that contained all laboratory samples obtained from each
potential study subject within the studies time frame. After successful creation of the
table, lab values that were not of interest in this study were then deleted. The below tables
details the laboratory biomarkers of interest:
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Hematology:

Chemistry:

Urinalysis:

Red Blood Count (RBC)
Hemoglobin
Mean Corpuscular Volume
(MCV)
Platelet count
White blood count (WBC)
PT/aPTT

Albumin
Urea Nitrogen (BUN)
Creatinine
Bilirubin-Direct/Indirect
Lactate Dehydrogenase
Total Protein

Hematuria
Proteinuria

Table 6. Laboratory Biomarkers
Subsequent to deleting the extraneous lab biomarkers, attention was given to the
specific date of the lab biomarker sample. Inclusion criteria for this study state that the
lab biomarker sample was to be obtained at the time of PSA sample; therefore PSA and
biomarker sample dates were compared to ensure time consistency. If the lab biomarkers
were not obtained at the same time as the PSA draw, they were deleted from the table
(Inclusion criteria).
After performing the above mentioned activities, an aggregate table was created
in MS Excel that contained the following information on each of the 2,575 potential
study subjects: patient ID number, age, histology category (PC, PIN. BPH, prostatitis),
PC stage (A, B, C, D), Gleason score (if PC positive), ethnicity (Caucasian, AfricanAmerican, Hispanic, Other), and the above lab biomarkers. This table was then utilized as
the base dataset for all subsequent data analysis, to include the below data reduction
strategies.
Data Reduction Strategies
Upon developing the base dataset for the data analysis portion of this study, data
reduction strategies were employed which ultimately left 1,378 participants available
(form 2,575 potential subjects) for statistical analysis. Over 500 prostate biopsies (541)
did not meet inclusion criteria because they where performed on men who did not have a
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PSA test value of 4.0 ng/dl or greater. Typical situations that would result in this scenario
includes men who had biopsies secondary to a suspicious DRE or TRUS, or biopsies
secondary to other reasons (e.g. patient request due to family history). There were 321
biopsies identified as “repeat biopsies”, which were then dropped from the study. Next,
prostate biopsies that were performed as a result of other genital urinary malignancies
(i.e. bladder, renal, ureter, and penile cancer) (N=260) were excluded. It is important to
note that the specific prompting for all prostate biopsies was confirmed through a detailed
record review of each prostate biopsy report within the VISTA system. These notes were
in narrative form and were validated by confirming the ICD-9 code for that event. Lastly,
participants without a full complement of laboratory biomarkers were excluded from the
study (N=75). At the completion of the above mentioned data reduction strategies, 1,378
participants were analyzed in this study. Figure 1 below is a schematic of the studies data
reduction process.
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Figure 1. – Data reduction strategy.
Box A
PC biopsies
n=2,575

PC with repeat
biopsy
n=321

Men with 2 biopsies= 247
Men with three biopsies= 52
Men with four biopsies= 16
Men with five biopsies= 6

Box C
Biopsy of only
Prostate
n=1994

Biopsy of
Bladder and
Prostate Urethra
n=260

Includes: Bladder, Renal,
Ureter, and Penile Cancer.

Box D
PSA value of
4ng/mL only
n=1453

Biopsy of
Prostate with
PSA <4ng/mL
n=541

Includes men who had
biopsies secondary to
suspicious DRE, TRUS, and
biopsies secondary to other
selection criteria.

Participants
without full
complement of
labs n=75

Missing value on one or more
laboratory biomarker of
interest.

Box B
PC initial biopsy
only n=2254

Box E
Participants
with full panel of
labs
N=1,378

Box F
Final Created Dataset-JHVA
Men with Prostate biopsies, PSA, and full
complement of labs White (n=971), Black (n=116),
Other (n=291)
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Other includes: Hispanic,
Asian, Pacific Islander,
Unknown, Refused, Blank,
and “Not Latino”.

6 - Statistical Procedures
Univariate, bivariate, logistical regression, linear regression, and receiver operator
characteristic curves were utilized to address the primary and secondary questions of
interest. All models were risk adjusted for ethnicity and age.
All data was abstracted from the VA hospital medical and laboratory records
computer system (VISTA). It was then entered into MS EXCEL for data verification and
review (See above for detailed explanation). Data was then imported into the SAS
statistical software program and univariate analysis was initiated. The use of this
descriptive analysis process allowed for careful review of data frequencies, measures of
central tendency, and distribution shapes. Additionally, identification of out of range
data, determination of the quantity of missing data, and accurate description of the study
population was achieved by utilizing this process.
Upon completion of the descriptive analysis, bivariate analysis was performed.
Bivariate analysis allows for testing of hypothesis 1 (see above), to determine the
statistical significance and degree of correlation between the independent variables under
review and the presence of prostate cancer.
Multivariate logistical regression was utilized to evaluate hypotheses 1 and 2.
Regression techniques were used to identify linear mathematical equations which best
described the relationship between the presence of PC and the independent predictor
variables. Regression diagnostic techniques were employed to increase the likelihood of
obtaining statistically sound and reliable analysis results. Binomial logistic regression
was also utilized, given the outcome variable (prostate disease status) was coded as a two
category outcome (PC yes= 1, PC no = 0).
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A complete model (including age, ethnicity, biomarkers, and any interaction
terms) was established initially. Exclusion of each covariate, one by one, was performed,
looking for a change in the overall – 2 Log Likelihood Ratio. A potential covariate was
permanently removed from the model development process if there was no effect on the
overall – 2 Log Likelihood value. This lack of change indicates the specific variable is
not contributing to the prediction of the outcome, and conversely, if there was a change
of statistical significance, the variable was included in the final model. Additionally,
interaction between covariates was assessed by creating combination variables, which
assessed for additive and multiplicative effects. To test the significant difference between
the full model and the final model, evaluation of the likelihood ratio p-value was
performed, in which a value greater than 0.05 indicated a satisfactory fit of the smaller
model.
Receiver operating characteristic (ROC) curves were employed to address the
second hypothesis. ROC curves are graphical tools which plots the sensitivity vs. 1- the
specificity for a binary classification system (as a function of changes in the cut-off value
threshold).39 This analysis technique was utilized to demonstrate the difference that exists
between the existing prostate cancer screening test (PSA alone) and the addition of a
secondary test (biomarker clinical decision rule) to assess at what degree we could expect
to improve PC screening by including the clinical decision rule into the PC screening
process.
Mean and medium values of all significant biomarkers was determined for each
PC stage subset to determine if there exists a gradient between advancing prostate cancer
severity and increasing systemic disease severity (hypothesis 3).
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Study Power
A power calculation was performed prior to the start of the study. The exposure
estimation was based on the mean number of JHVA male individual patients with
abnormal laboratory values noted during 1998 through 2004. The denominator was the
total number of male patients who underwent laboratory testing during the same time
period. The calculation allowed us to conclude that the study has sufficient power (>0.80)
to accurately detect an odds ratio of 2 with 95 percent confidence in the case population
of 1,378 subjects is present. In addition, this calculation indicated that our study is
designed and equipped to deal with larger than expected censured data loss, thus if a
number of participants would have been lost, adequate study power will remain. An alpha
value of 0.05 was the significant cutoff level throughout the analysis.
7 - Variables
Dependent
Hypothesis I & Hypothesis II - The outcome variable, prostate disease status; was
defined as 1, for histological identification of PC and 0, for histological identification of
BPH, PIN, and other non cancerous pathologies (i.e. prostatitis).
Hypothesis III – The outcome variable, prostate cancer severity, was defined as 3,
(PC positive, organ confined, low grade); 2, (PC positive, palpable, moderate grade); 1,
(PC positive, palpable, locally spread disease, moderate grade); 0, (PC positive, distant
spread, high grade).
Independent
The independent variables were treated as continuous, categorized, and binomial
in the analysis. There were 14 independent variables available for inclusion as predictor
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variables in the logistical regression models. Four variables that were initially scheduled
for analysis were dropped due to excessive participants with missing data (Pro-thrombin
time/Partial pro-thrombin time (PT/aPTT), Folate, Lactate Dehydrogenase, and Total
Protein). The 14 independent variables are outlined in Table 7 below.
ID

Age

Continuous

Histology
Stage
Gleason

Categorical
Categorical
cat/continuous

Ethnicity
ALB
TBILI
CREAT
FLT
HGB
LDH
MCV
PLT
PSA
RBC
UREAN

Categorical
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous
Continuous

HMTU

Recoded

PRTU
WBC
PCYes
Black
Hispanic
Other/Unknown

Recoded
Continuous
Binary flag
Binary flag
Binary flag
Binary flag

HMTU2
(Hematuria)

PRTU2

Age for subjects and was be calculated by
subtracting the birth date from the date of
disease determination.
Disease status will be coded as 1-‘prostate
cancer’, 2-‘PIN’, 3-‘BPH’, 4-‘control group’.
1-Stage A, 2-Stage B, 3-Stage C, 4-Stage D
1-10
Obtained directly from the VA EMR. Coded
as ‘White”, ‘Black’, ‘Hispanic’, and ‘Other’.

Original data: 1 + H, LG, lg, MOD, NEG,
neg., SM and TR.
Original data: 1+ H, 100.0 H, 2+ H, 3+H, 30.0
H, >300 H, NEG, neg., TR
PC Yes=1, PC No = 0

Categorical

Recoded- NEG, neg.=0 (negative), 1+H and
TR=1 (trace), SM=2 (small), MOD=3
(moderate), lg and LG=4 (large)

Categorical

Recode of PRTU. NEG and neg.=0 (negative),
TR=1 (trace), 1+H=2 (moderate), 2+ H=3, 3+
H and 100.0 H and >300 H and 30.0 H=4

Table 7. Coding of the criterion and independent variables
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8 - Summary
The overall aim of this study is to improve the efficiency of prostate cancer
screening through the development of a clinical decision rule that is based on an elevated
PSA and a predictive set of clinical biomarkers. This is a cross-sectional study evaluating
men from the James Haley VA healthcare network from January 1, 1998 through April
15, 2005. These men have undergone prostate biopsies as a result of an elevated PSA
screening test (>4ng/dL). The target population is all men who utilize the VA healthcare
system throughout the U.S. There are three hypotheses under evaluation:
H1: Specific lab biomarkers among cases of prostate cancer will differ
significantly from those patients without prostate cancer.
H2: In men with elevated PSA values, the addition of specific lab biomarkers
will improve the effectiveness of predicting prostate cancer when compared to
PSA alone.
H3: There exists a gradient between specified lab biomarkers and increasing
levels of prostate cancer.
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Chapter IV Results
4.1 – Population Characteristics
Demographics
Demographic data is outlined below in table 8. After study exclusions (see
chapter III), there were 1,378 men available for analysis. The age range of the subjects
was 40-95 (mean=68, SD=12). Most of the men had either prostatitis, BPH, or stage A
PC. Prostate cancer (stage B, C, D) accounted for 20.6% of all diagnosis. The study
population was largely Caucasian men (study total=70.75%, PC=69.4%, PIN=71.73%,
BPH=74.82%, prostatitis=69.29%). Age at diagnosis (PC stage A group=68.37, PC stage
B group=69.73, PC stage C group=67.73, stage D group 67.88, PIN group=67.75, BPH
group=67.83, prostatitis group=68.17) was comparable across all diagnosis groups.

No. Subjects
Ethnicity*
Caucasian
African
American
Hispanic
Other
Mean
Age***
SD Age

Prostatitis
342

BPH
282

PIN
138

PC Stage A
332

PC Stage B
220

PC Stage
C
48

PC Stage
D
16

237 (69%)

211(75%)

99 (72%)

238 (72%)

149 (68%)

31(65%)

10 (63%)

18 (5%)
22 (6%)
65 (20%)

19 (7%)
14 (5%)
38 (14%)

13 (9%)
7 (5%)
19 (14%)

34 (10%)
15 (5%)
45 (13%)

22 (10%)
11 (5%)
38 (17%)

7 (15%)
1 (2%)
9 (18%)

4 (25%)
1 (6%)
1 (6%)

68.17
8.54

67.83
8.19

67.75
8.49

68.37
8.99

69.73
9.36

67.73
9.39

67.88
10.6

Table 8. Demographics of Study Participants by Prostate biopsy results
* P-value < 0.05
** P-value <0.01
*** Not statistically significant
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Table 9 (below) outlines the mean value and standard deviation of all continuous
laboratory biomarkers by the prostate biopsy results. The mean values of albumin,
hemoglobin (HGB), RBC count, creatinine, and folate all decreased as the stage of PC
increased. Conversely, the mean value of PSA increased as the stage of PC increased. For
the laboratory biomarkers MCV, BUN, platlet count, WBC, LDH, and bilirubin, their
mean values fluctuated without demonstrating any particular trend.
A test for trend significance was additionally performed on table 8. As the
prostate biopsy result increased from prostatitis to stage D PC, significant trends (p-value
<.05) were noted for the mean value of HGB, creatinine, PSA, and BUN. Conversely, the
lab biomarkers RBC, MCV, albumin, WBC, bilirubin, and platlet count did not
demonstrate statistically significant trend changes.
Prostatitis BPH
N=342
N=282

PIN
N=138

PC
Stage A
N=332

PC
Stage B
N=220

Albumin
Mean
SD

4.00
0.38

3.98
0.37

4.09
0.37

4.04
0.38

4.00
0.42

3.95
0.39

3.90
0.42

HGB *
Mean
SD

14.27
1.54

14.24
1.76

14.30
1.68

14.17
1.66

13.70
1.87

12.59
2.20

12.84
14.08

RBC
Mean
SD

4.67
0.46

4.65
0.52

4.76
0.52

4.69
0.50

4.63
0.57

4.58
0.44

4.50
0.67

Creatinine*
Mean
SD

1.25
0.70

1.16
0.32

1.20
0.35

1.16
0.56

1.15
0.34

1.14
0.39

1.13
0.20

8.06
6.74

7.99
11.20

7.67
4.58

9.70
11.66

14.12
29.27

21.85
30.21

44.03
48.71

PSA*
Mean
SD
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PC
Stage C
N=48

PC
Stage D
N=16

Prostatitis BPH
N=342
N=282

PIN
N=138

PC
Stage A
N=332

PC
Stage B
N=220

PC
Stage C
N=48

PC
Stage D
N=16

MCV
Mean
SD

90.78
4.65

91.13
5.35

90.09
5.79

91.17
5.05

90.98
6.11

90.23
4.18

92.24
4.99

Bilirubin
Mean
SD

0.66
0.40

0.65
0.30

0.60
0.25

0.66
0.35

0.67
0.35

0.65
0.34

0.60
0.30

BUN*
Mean
SD

17.98
6.93

17.60
7.90

17.23
6.50

16.53
6.56

17.40
6.73

16.00
6.74

15.97
4.54

Platlet
Mean
SD

230.45
59.16

227.63
61.56

240.81
84.31

226.54
62.26

232.50
69.25

234.30
68.07

235.44
50.76

WBC
Mean
SD

7.24
2.11

7.11
2.17

7.42
3.24

7.19
2.42

7.13
2.08

10.41
17.78

7.37
1.84

Folate
Mean
SD

12.93
5.44

12.56
5.78

12.31
5.29

13.37
5.25

11.92
5.43

10.71
5.44

10.03
4.99

LDH
Mean
SD

426.91
375.09

424.78
144.84

371.84
185.54

404.60
155.38

406.41
158.19

392.11
170.98

393.33
73.76

Table 9. Mean value and SD of Lab biomarkers by Prostate biopsy results
* - Trend significance (P-value <.05)
Testing the Hypothesis
4.2 - Hypothesis 1: Among VA patients who have undergone prostate biopsies
secondary to a PSA value of >4ng/dL, specified lab biomarkers* among cases of
prostate cancer will differ significantly from those among VA patients without
prostate cancer.
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Crude Odds Ratios (with 95 % CI) for the association of each laboratory
biomarker with prostate cancer is presented in three ways:
•

Method 1 - all stages of PC vs. non-cancerous prostate conditions

•

Method 2 - PC stages (B, C, D) vs. other (stage A PC, PIN, BPH, and
prostatitis)

•

Method 3 - PC stages (B, C, D) vs. non-cancerous conditions (PIN, BPH,
prostatitis). Stage A PC is excluded in this analysis method. This data is
outlined in Table 10-12, respectively.

Method 1
There were 3 independent variables in this analysis that were statistically
significantly related to the PC positive cases when compared to the control group (PC
negative: PIN, BPH, and prostatitis) (Table 10). Initial crude analysis revealed
hemoglobin, PSA, and serum BUN were significantly related; while age, hematuria,
albumin, creatinine, MCV, platlet count, RBC count, bilirubin, and WBC were not
statistically significant.
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Covariates Included Odds Ratio OR 95% Confidence Interval
HGB *
0.87
(0.82-0.93)
AGE
1.01
(0.99-1.02)
PSA*
1.04
(1.02-1.06)
Hematuria
0.95
(0.86-1.06)
Proteinuria
0.94
(0.83-1.07)
Albumin
1.03
(0.78-1.36)
Creatinine
0.76
(0.76-1.01)
MCV
1.01
(0.99-1.03)
PLT
1.00
(0.99-1.00)
RBC
0.92
(0.75-1.13)
Total Bilirubin
1.14
(0.84-1.55)
BUN*
0.98
(0.96-0.99)
WBC
1.01
(0.98-1.05)
Table 10. Odds Ratio and 95% CI for Method 1: PC (all stages) vs. non-cancerous
conditions, per laboratory unit
* P-value significance at 0.05
** P-value <0.01
*** P-value <.001
Method 2
When the stage A PC subjects were placed in the comparison group (leaving stage
B, C, and D PC subjects as the ‘cases’), there were 5 independent variables that
demonstrated statistically significant relationships with the PC positive cases (when
compared to the control group: stage A PC, PIN, BPH, and prostatitis). Initial bivariate
analysis revealed hemoglobin, age, PSA, hematuria, and RBC count were the significant
biomarkers, while albumin, creatinine, MCV, platlet count, bilirubin, BUN, and WBC
were not.
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Covariates Included Odds Ratio OR 95% Confidence Interval
HGB *
0.79
(0.74-0.85)
AGE*
1.02
(1.01-1.03)
PSA*
1.04
(1.03-1.05)
Hematuria*
1.23
(1.10-1.38)
Proteinuria
1.16
(1.00-1.34)
Albumin
0.77
(0.55-1.08)
Creatinine
0.76
(0.52-1.12)
MCV
1.00
(0.97-1.03)
PLT
1.00
(0.99-1.00)
RBC*
0.76
(0.59-0.98)
Total Bilirubin
1.15
(0.80-1.66)
BUN
0.99
(0.98-1.01)
WBC
1.03
(0.99-1.06)
Table 11. Odds Ratio and 95% CI for Method 2: PC (stage B, C, D) vs. other (PC
stage A, PIN, BPH, prostatitis), per laboratory unit
* P-value < 0.05
** P-value <0.01
*** P-value <0.001
Method 3
When the stage A PC subjects were dropped from the analysis process (leaving
stage B, C, and D PC subjects as the ‘cases’, and PIN, BPH, and prostatitis subjects as the
‘controls’), there were 3 independent variables that were significantly related to the PC
positive cases. Initial bivariate analysis revealed hemoglobin, PSA, and hematuria were
significantly related to PC, while age, proteinuria, albumin, creatinine, MCV, platlet
count, bilirubin, BUN, and WBC were not (See table 12 below).
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Covariates Included Odds Ratio OR 95% Confidence Interval
HGB *
0.79
(0.73-0.85)
AGE
1.02
(1.00-1.03)
PSA*
1.06
(1.04-1.08)
Hematuria*
1.15
(1.02-1.29)
Proteinuria
1.09
(0.94-1.27)
Albumin
0.83
(0.58-1.18)
Creatinine
0.68
(0.46-1.02)
MCV
1.00
(0.98-1.03)
PLT
1.00
(0.99-1.00)
RBC
0.77
(0.59-1.01)
Total Bilirubin
1.19
(0.81-1.75)
BUN
0.99
(0.97-1.01)
WBC
1.02
(0.99-1.06)
Table 12. Odds Ratio and 95% CI for Method 3: PC (stage B, C, D) vs. noncancerous conditions (PIN, BPH, prostatitis), per laboratory unit (stage A PC not in
analysis)
* P-value significance at 0.05
Table 13 below summarizes the laboratory biomarkers which demonstrated a
statistically significant relationship with PC. The lab biomarkers proteinuria, albumin,
creatinine, platlet count, bilirubin, and WBC were not significantly related to PC in the
crude analysis.
Independent
Method 1
Method 2
Method 3
Variable
Hemoglobin
***
***
***
(HGB)
RBC count
*
BUN
*
Hematuria
*
*
PSA
***
***
***
Age
*
*
Table 13. Summary table of independent variables that demonstrate statistically
significant relations with PC (by analysis methods 1-3)
* P-value <0.05
** P-value <0.01
***P-value <0.001
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4.3 - Hypothesis 2: Among VA patients who have undergone prostate biopsies
secondary to a PSA value of >4ng/dl, the addition of specified lab biomarkers* will
improve the effectiveness of predicting the presence of prostate cancer when
compared to PSA alone.
Comparison
Method 1
Method 2
Method 3
Groups
PC Cases/Total
616/1,378
284/1,378
284/1,046
biopsies
Positive Predictive 44.7%
20.6%
27.2%
Value
Table 14. Positive Predictive Value of PSA > 4ng/dL
Method 1: PC (all stages) vs. non-cancerous conditions (PIN, BPH, prostatitis)
Method 2: PC (stage B, C, D) vs. other (stage A PC, PIN, BPH, prostatitis)
Method 3: PC stage (B, C, D) vs. non-cancerous conditions (PIN, BPH, prostatitis)
Table 14 outlines the PPV of PSA (4ng/dL) alone for detecting prostate cancer.
This PPV was evaluated 3 different ways:
•

Method 1 - all stages of PC vs. non-cancerous prostate conditions

•

Method 2 - PC stages (B, C, D) vs. other (stage A PC, PIN, BPH, and prostatitis)

•

Method 3 (stage A PC excluded) - PC stages (B, C, D) vs. non-cancerous
conditions (PIN, BPH, prostatitis), respectively.
The positive predictive value was decreased significantly when stage A PC was

not considered as a case. In particular, the PPV decreased by 24.1% when the stage A PC
group was considered as in the comparison group (non-diseased).
To begin the regression process, a full model was assimilated, including all
laboratory biomarkers, age, and ethnicity. Multiple models were then run, excluding each
covariate, one by one, to assess the change of the -2 Log Likelihood value and the Cstatistic. The evaluation process continued until the most parsimonious model with the
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lowest -2 Log Likelihood value and highest C-statistic was determined for each of the 3
analysis methods (tables 15-17 below).
Interaction terms were evaluated for each of the 3 analysis methods. While the
overall change to the of the -2 Log Likelihood value and the C-statistic were minimal and
not statistically significant, the interaction between age and HGB and age and PSA were
significant (p-value <.05). For a 50 year old man, the OR for HGB and PSA would be
(1.02, 95%CI 1.01-1.04, respectively. For a 70 year old man, the comparable OR would
be (1.03, 95%CI 1.01-1.04), respectively. This interaction was noted to be of quantitative
rather than qualitative significance.

ML
Parameter
Est.
SE
OR
95% CI
C stat -2 LL
Intercept
-7.9494
1.88
xx
xx
0.68 1777.339
HGB**
-0.3519
0.06
0.70 (0.63-0.79)
RBC**
0.9227
0.21
2.52 (1.67-3.78)
Hematuria** -0.2874
0.15
0.75 (0.56-1.01)
Creatinine** -0.4393
0.17
0.65 (0.47-0.89)
Black**
0.6336
0.21
1.89 (1.25-2.90)
PSA**
0.0408
0.08
1.04 (1.03-1.06)
AGE**
0.0196
0.01
1.02 (1.01-1.03)
MCV**
0.0663
0.02
1.07 (1.04-1.10)
Albumin***
0.2871
0.16
1.33 (0.98-1.82)
Table 15. Best fit Logistical Regression for Method 1: Risk of PC with Lab
biomarkers and 95% CI, per laboratory unit
Method 1: PC (all stages) vs. non-cancerous conditions (PIN, BPH, prostatitis)
** p-value <.05, *** Not significant
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Parameter
ML Est.
SE
OR
95% CI
C Stat
-2 LL
Intercept
-5.1041
xx
xx
xx
0.713
1276.366
HGB**
-0.3784
0.05
0.69
(0.62, 0.76)
RBC**
0.7641
0.21
2.15
(1.43, 3.23)
Creatinine**
-0.6069
0.23
0.55
(0.35, 0.85)
PSA **
0.0325
0.01
1.03
(1.02, 1.05)
Age**
0.0183
0.01
1.02
(1.01, 1.04)
MCV**
0.0488
0.02
1.05
(1.02, 1.08)
Black***
0.3612
0.24
1.44
(0.90, 2.31)
Table 16. Best fit logistical regression model for Method 2: Risk and 95% CI for PC
with lab biomarkers, per laboratory unit
* P-value <0.05, ** P-value <0.001, *** Not significant

Parameter
ML Est.
SE
OR
95% CI
C stat
-2 LL
Intercept**
-6.8083
2.2821
xx
xx
0.742
1077.58
HGB***
-0.4720
0.0658
0.62
(0.55, 0.71)
RBC**
1.1051
0.2516
3.02
(1.84, 4.94)
Creatinine** -0.8150
0.2543
0.44
(0.27, 0.73)
Black*
0.6092
0.2664
1.84
(1.09, 3.10)
PSA***
0.0540
0.0090
1.06
(1.04, 1.08)
AGE*
0.0238
0.0010
1.02
(1.01, 1.04)
MCV**
0.0658
0.0181
1.07
(1.03, 1.11)
Table 17. Best fit logistical regression model for Model 3: Risk and 95% CI for PC
with Lab biomarkers, per laboratory unit
Method 3: PC stage (B, C, D) vs. non-cancerous conditions (PIN, BPH, prostatitis)
PC stage A excluded from analysis
* P-value <.05
** P-value <.01
*** P-value <.001
The ROC curves below demonstrate the validity that was yielded for analysis
method 1-3, respectively. These ROC curves demonstrates the difference that exists
between the existing prostate cancer screening test (PSA alone) and the secondary
screening test to assess at what degree can we expect to improve PC screening by
including this secondary rule into the PC screening process (see figures 2-7 below).
Confidence intervals between PSA alone and the clinical decision rule models (PSA + lab
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biomarkers) did not overlap and were statistically significantly different. The ROC AUC:
Method 1 PSA alone 0.59, (95% CI 0.55, 0.61) to CDR (PSA+ significant lab
biomarkers) 0.68 (95% CI 0.65, 0.71); Method 2 PSA alone 0.63, (95% CI 0.58, 0.66) to
CDR (PSA+ significant lab biomarkers) 0.72 (95% CI 0.68, 0.75); Method 3 PSA alone
0.64 (95% CI 0.59, 0.68) to 0.74 CDR (PSA+ significant lab biomarkers) (95% CI 0.71,
0.78).
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ROC Curves: Figures 2-7.

Figure 2. Diagnostic statistics = ROC curve of PSA Alone - Method 1

Figure 3. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 1
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Figure 4.Diagnostic statistics = ROC curve of PSA Alone - Method 2

Figure 5. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 2
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Figure 6. Diagnostic statistics = ROC curve of PSA Alone - Method 3

Figure 7. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 2
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For determining the ideal cut-points for recommending prostate biopsy, 4
different cut-points where chosen, each providing either increased sensitivity or
specificity. The cut-points are presented in four ways:
•

Cut-point 1 – The maximum likelihood ratio. This was determined by dividing
the sensitivity by 1- the specificity (SEN/1-SPC), thus maximizing the quotient.

•

Cut point 2 – The probability that yielded a sensitivity of approximately 90%
with the highest corresponding specificity.

•

Cut point 3 - The probability that yielded a sensitivity of approximately 80% with
the highest corresponding specificity.

•

Cut point 4 - The probability that yielded a specificity of approximately 80% with
the highest corresponding sensitivity. This data is outlined in Table 18- 19,
respectively.
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Method 1
Method 2
Method 3
Cut-point 1 (MLE)
Probability .45
Probability .41
Probability .42
Sensitivity
52.1 %
18.3 %
33.5 %
Specificity
74.0 %
96.2 %
93.4 %
PPV
61.8 %
55.3 %
65.5 %
NPV
65.7%
81.9 %
79.0 %
Cut-point 2 (Sen.
Probability .33
Probability .13
Probability .17
90%)
Sensitivity
90.9 %
89.8 %
90.1 %
Specificity
17.6 %
28.0 %
31.1 %
PPV
47.1 %
20.6 %
32.8 %
NPV
70.5 %
91.3 %
89.4 %
Cut-point 3 (Sen.
Probability .37
Probability .15
Probability .20
80%)
Sensitivity
80.5 %
78.2 %
78.9 %
Specificity
37.1 %
45.0 %
49.9 %
PPV
50.9 %
28.7 %
37.0 %
NPV
70.2 %
88.8 %
86.4 %
Cut-point 4 (Spc.
Probability .48
Probability .23
Probability .29
80%)
Sensitivity
39.9 %
45.8 %
52.1 %
Specificity
81.4 %
79.5 %
81.8 %
PPV
63.4 %
36.7 %
51.6 %
NPV
62.6 %
85.0 %
82.1 %
Table 18. Sensitivity, Specificity, PPV, and NPV for probability cut-off points

Method 1
Method 2
Method 3
Crude PPV
44.7 %
20.6 %
27.2 %
Cut-point 1
61.8 %
55.3 %
65.5 %
Cut-point 2
47.1 %
20.6%
32.8 %
Cut-point 3
50.9 %
28.7%
37.0 %
Cut-point 4
63.4 %
36.7%
51.6 %
Table 19. Comparison of PPV between PSA (>4ng/dL) and cut-points 1-4 by
analysis method
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4.4 - Hypothesis 3: Among VA cases of histologically confirmed prostate cancer,
there exists a gradient between specified lab biomarkers* and increasing stage of
prostate cancer.
To evaluate hypothesis III, the mean values of each specified lab parameter (with
accompanying 95 % CI) was determined for each PC stage. If there exists a gradient
between the lab biomarkers and increasing stage of PC severity, one would expect to see
a change in the mean value of the biomarker (away from the normal expected level) as
the PC stage increases. This set of circumstances is seen in mean change of the lab
biomarkers HGB, RBC, Albumin, and PSA (Table 20, below).
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Albumin
Mean
SD
95%CI
HGB
Mean
SD
95%CI
RBC
Mean
SD
95%CI
Creatinine
Mean
SD
95%CI
PSA
Mean
SD
95%CI

PC Stage A
N=332

PC Stage B
N=220

PC Stage C
N=48

PC Stage D
N=16

4.04
0.38
(4.00, 4.08)

4.00
0.42
(3.96, 4.05)

3.95
0.39
(3.84, 4.06)

3.90
0.42
(3.69, 4.11)

14.17
13.70
1.66
1.87
(14.00, 14.35) (13.45, 13.95)

12.59
2.20
(11.97, 13.21)

12.84
14.08
(5.94, 19.74)

4.69
0.50
(4.64, 4.74)

4.63
0.57
(4.55, 4.71)

4.58
0.44
(4.46, 4.70)

4.50
0.67
(4.17, 4.83)

1.16
0.56
(1.10, 1.22)

1.15
0.34
(1.11, 1.20)

1.14
0.39
(1.03, 1.25)

1.13
0.20
(1.03, 1.23)

9.70
11.66
(8.45, 10.95)

14.12
29.27
(10.25, 17.99)

21.85
30.21
(13.31, 30.39)

44.03
48.71
(20.16, 67.90)

MCV
Mean
91.17
90.98
90.23
92.24
SD
5.05
6.11
4.18
4.99
95%CI
(90.63, 91.71) (90.17, 91.79) (89.05, 91.41) (89.79, 94.69)
Bilirubin
0.66
0.67
0.65
0.60
Mean
SD
0.35
0.35
0.34
0.30
95%CI
(0.28, 1.04)
(0.62, 0.72)
(0.60, 0.70)
(0.45, 0.75)
BUN
Mean
16.53
17.40
16.00
15.97
SD
6.56
6.73
6.74
4.54
95%CI
(15.82, 17.24) (16.51, 18.29) (17.91, 14.09) (13.74, 18.20)
Platlet
Mean
226.54
232.50
234.30
235.44
SD
62.26
69.25
68.07
50.76
95%CI
(219.8, 233.2) (223.4, 241.7) (215.1, 253.6) (210.6, 260.3)
WBC
Mean
7.19
7.13
10.41
7.37
SD
2.42
2.08
1.78
1.84
95%CI
(6.93, 7.45)
(6.86, 7.40)
(9.91, 10.91)
(6.47, 8.27)
Table 20. Mean value, SD, and 95% CI of Lab biomarkers by PC stage
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A trend analysis was performed to determine whether or not the change seen with
lab biomarkers HGB, RBC, Albumin, and PSA was statistically significant. This trend
analysis was performed through linear regression modeling. These linear models were
analyzed by first coding each continuous laboratory biomarkers as the criterion variable,
with the PC stage coded as the predictor variable. The model results suggest that PC stage
is a significant statistical predictor for gradient changes in the laboratory biomarkers
HGB, RBC count, albumin, and PSA (table 21, below). The four subsequent graphs
further demonstrate the change in mean value by PC stage for each significant lab
biomarker.
Criterion
Parameters
HGB*
RBC*
MCV- NS
Creat. - NS
Albumin*
PSA*

Parameter
Estimate
-0.58752
-0.06291
-0.11639
-0.009
-0.0483
7.458

SE
0.099
0.028
0.292
0.026
0.021
1.227

T value
-5.96
-2.22
-0.4
-0.37
-2.26
6.08

R
square
0.0547
0.0079
0.0003
0.0002
0.0083
0.0568

Adjusted
R square
0.0532
0.063
-0.00014
-0.0014
0.0067
0.0552

F value
35.54
4.91
0.16
0.14
5.12
36.95

Biomarker
change
0.555
0.939
XX
XX
0.953
1733.6

Table 21. Results of Linear Regression modeling of lab biomarker by PC stage
* P-value <.05
** P-value <.001
*** P-value <.001
NS-Not statistically significant
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Figure 8. Mean Hemoglobin value by PC stage
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Figure 9. Mean Albumin value by PC stage

92

Stage III
n=48

Stage IV
n=16

Mean RBC count by Stage (N=616)
6
Mean RBC count

5
4
3
2
1
0
Stage I (N=332)

Stage II (N=220)

Stage III (N=48)

Stage IV (N=16)

Figure 10. Mean RBC count by PC stage
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Figure 11. Mean PSA value by PC stage
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Chapter V: Discussion
5.1 - Introduction (Chapter I-III Review)
A search of peer reviewed published literature failed to identify any studies that
evaluate whether (or not) combinations of laboratory biomarkers, used in concurrence
with an elevated PSA, increase the detection of screened identified PC. However,
previous research has demonstrated that specific systems are altered as PC increases in
stage and severity.29, 30, 32, 92 In particular, anemia (either iron defiency or anemia of
chronic disease) is a frequent complication of PC, and hematuria is a common finding in
patients with prostate tumors that have spread outside of the prostate capsule, but have
not yet spread to distant body regions.33 In multiple published studies, decreased
hemoglobin has been reported as an independent risk factor for decreased survival
outcomes in patients with hormone refractory prostate cancer.91 Moreover, previous
research has demonstrated that PSA has limitations (e.g. poor validity and reliability) and
there is room for improvement. 1, 8, 11
A primary goal of PC screening is to detect the cancers before they are too
advanced for treatment, and to bypass the tumors that are not destined to become
deleterious in the patient’s lifetime.106 With that stated, delineation between the different
types of PC is difficult, but of paramount importance. Earlier PSA research by Catalona,
the U.S. Preventive Task Force and more recent work by Thompson, Carter, the PLCO
(and others), has been critical in improving our ability to identify PC at earlier disease
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stages.11, 25, 106 However, there is continued debate over the utility of PSA as a screening
tool for prostate cancer.8 Is it the best currently available tool for the detection of preclinical PC? This debate is likely to continue until the results of the PLCO trial are
released (tentatively scheduled for 2014).
How can PC screening be improved? Despite a wealth of published literature that
has evaluated PSA and argued against its use as a PC screening tool, PSA remains the
mainstay for clinicians for PC screening. Thus, the focus must be on augmenting PSA,
not replacing it altogether. Prior attempts at improving PC screening have focused on
replacing PSA with a new test. Tools such as PSA velocity, PSA density, Free/Total PSA
ratio have all shown promise in studies for improving PC screening results, but difficult
implementation and a lack of universal acceptance among clinicians have hindered their
incorporation into daily clinical practice.7, 23, 26, 27, 40, 41, 41, 86
Have researchers and clinicians made the most of all available information when
evaluating a patient for prostate cancer? Routinely ordered lab panels (complete blood
count, basic metabolic panels, and urinalyses) all contain biomarkers that change in value
when diseases associated with prostate cancer are present. Yet these biomarkers have not
been utilized when evaluating a patient for PC. Many previous studies have accurately
described PSA elevations as ‘specific to a condition of the prostate’.8, 18 However, these
PSA elevations are not specific to prostate cancer. In what may hold the key to improving
the overall yield of PC screening; evaluating changes in certain laboratory biomarkers
values (in the presence of an elevated PSA) that are associated with diseases that are a
product (either directly or indirectly) of PC spread may provide a wealth of important
information that can improve the validity and reliability of PC screening.
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5.2 – Review of Main Findings (Chapter IV)
A primary goal of PC screening is to detect the cancers before they are too
advanced for treatment, and to overlook the tumors that are not destined to become
deleterious in the patient’s lifetime.106 With that stated, 2 questions arose during the
course of this study. Given that stage A (non-palpable, organ confined) PC often is
undetectable and offers little biological evidence of its presence, does its inclusion in this
analysis mitigate the difference between the clinically important PC and non-cancerous
prostate disease? Are the laboratory biomarkers under evaluation related more to more
advanced (or aggressive) PC stages? To answer these questions, the statistical analysis
procedures were performed utilizing 3 different methods. For method 1, stage A PC was
included as a ‘case’, for method 2, stage A PC was included as a ‘control’, and in method
3, stage A PC was excluded from the analysis altogether. The intent in evaluating the data
by multiple methods is to develop a clinical decision rule that can provide clinicians and
patients information on the probability of the presence/absence of PC, and if it is PC, the
likely stage of the cancer, prior to prostate biopsy.
This study hypothesized that specific lab biomarkers among cases of PC would
differ significantly from those patients without PC. The countering null hypothesis states
the specific laboratory biomarkers do not differ between the PC patients and noncancerous patients. This hypothesis was evaluated by both bivariate (e.g. one outcome
variable, one independent variable) and multivariate analysis techniques. Initially,
analysis method 1 demonstrated that HGB, PSA, and serum BUN were significant
variables (see chapter IV table 10). The relationships were then re-evaluated with
multiple logistic regression, and a more precise picture began to develop. Additional
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significant predictor variables emerged, and serum BUN was not significant in the
multivariate model. Throughout the method 1 modeling process, HGB (OR=1.42 95%CI
1.27-1.59), RBC count (OR=2.52 95%CI 1.67-3.78), PSA (OR=1.04 95%CI 1.03-1.05),
serum creatinine (OR=1.55 95%CI 1.12-2.15), and the ethnicity variable ‘Black’
(OR=1.88 95%CI 1.25-2.85) were significantly related to the PC group. Under conditions
where all other predictor variables are held constant; both HGB (point estimate -.3519 pvalue <.0001) and creatinine (point estimate -.4393 p-value .008) demonstrated increased
PC risk with a 1 unit negative change in their value; while RBC count (point estimate
.9227 p-value <.0001), age (point estimate .0196 p-value <.005), PSA value (point
estimate .0408 p-value <.005), MCV level (point estimate .066 p-value <.0001), and
serum albumin (point estimate .2871 p-value .071) demonstrated increased PC risk of 1
unit positive increase in their respected values.
Analysis method 2 (stage A included in the comparison group) crude analysis
demonstrated HGB, PSA, RBC count, hematuria, and age were significant variables (see
chapter IV, table 11). Multiple regression modeling demonstrated HGB (OR 0.68 95%CI
0.62, 0.76), RBC (OR 2.15 95% CI 1.43, 3.23), serum creatinine (OR 0.545 95%CI 0.35,
0.85), PSA (OR 1.033 95%CI 1.02, 1.05), MCV (OR 1.05 95%CI 1.02, 1.08), and age
(OR 1.018 95%CI 1.01, 1.04) were all significant after all other predictor variables were
held constant.
Analysis method 3 (stage A excluded from the analysis); the crude analysis
revealed HGB, PSA, and hematuria were significant variables (see chapter IV, table 12).
Multiple regression modeling demonstrated HGB (OR 0.62 95%CI 0.55, 0.71), RBC (OR
3.02 95% CI 1.84, 4.94), serum creatinine (OR 0.44 95%CI 0.27, 0.73), PSA (OR 1.06
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95%CI 1.04, 1.08), MCV (OR 1.07 95%CI 1.03, 1.11), and age (OR 1.02 95%CI 1.01,
1.04) were all significant after all other predictor variables were held constant.
The second hypothesis stated ‘the addition of specific lab biomarkers will
improve the effectiveness of predicting prostate cancer when compared to PSA alone’.
The countering null hypothesis is, ‘there is no difference between the two models’. To
address this question, ROC curves were employed. ROC curves measure the probability
of correct diagnostic classification, i.e. the test accuracy.114 I compared the ROC curve of
the best fit model for analysis methods 1-3 to the ROC curves of PSA (4ng/dL) to
determine if the area under the curve (AUC) between the models and the PSA model are
significantly different. In addition, the 95 % CI was determined for all models. The AUC
increased from: Method 1 PSA alone 0.59, (95% CI 0.55, 0.61) to CDR best fit model
0.68, (95%CI 0.65, 0.71); Method2 PSA alone 0.63, (95% CI 0.58, 0.66), to CDR best fit
model 0.68, (95% CI 0.68, 0.75); Method 3 PSA alone 0.64, (95%CI 0.59, 0.68), to CDR
best fit model 0.74 (95% CI 0.71, 0.78). This indicates that the difference between the
models is significant, thus the null hypothesis of no difference is rejected. In addition to
the ROC curve, the validity (sensitivity/specificity) and predictive values (positive
predictive value/negative predictive value) were determined for the best fit model. For
the PSA only model, one can only determine the positive predictive value, given patients
with a PSA less than 4ng/dL are not routinely forwarded for prostate biopsy. The PPV of
PSA (>= 4ng/dL) decreased from 44.7% (method 1) to 20.6% (method 2). This indicates
PSA is less effective as a tool for identifying the more clinically relevant PC (stage B, C,
and D). Conversely, looking at method 2, cut-point 1 (see chapter IV, table 18) the
sensitivity of this model was 18.3%, specificity was 96.2%, NPV 81.9%, and a PPV at
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55.3% These values are increased over the validity and predictive values that have been
published in previous studies that attempted to clarify the ambiguity surrounding PSA
sensitivity and specificity. This indicates that this model could improve our ability to
detect clinically important PC. Moreover, depending on the cut-off point, the study offers
hope that the number of unnecessary biopsies performed within the JH VA could be
reduced.
The third hypothesis under evaluation was whether there exists a gradient of
change between the significant lab biomarkers and increasing levels of PC. Four of the
laboratory biomarkers did demonstrate a gradient with increasing stage of PC
(hemoglobin, RBC, PSA, and albumin). For the stage IV PC, the small number of cases
led to unstable point estimates, large confidence intervals, and it is suspected that if the
numbers in this group increased, a similar gradient trend would materialize.
To evaluate the statistical significance of the gradient, linear regression analysis
was performed. Each continuous laboratory biomarker was modeled as the outcome
variable, with PC stage (A-D) modeled as the predictor variable. In addition to PSA, the
variables hemoglobin, RBC count, and albumin demonstrated a significant difference
between each PC stage (see chapter IV, table 21). These results indicate that the degree of
change between the reference ‘normal’ value and the observed lab value could provide
valuable insight for detecting PC, and improve our ability to differentiate between
indolent PC and clinically relevant PC.
These results suggest that evaluation of additional laboratory biomarkers (in
conjunction with an elevated PSA) might improve our ability to detect prostate cancer;
while also decreasing the number of non-diagnostic prostate biopsies. Moreover, the
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results seem to indicate that the evaluated biomarkers may be more helpful in detecting
clinically relevant cancer. After evaluating stage A PC in the comparison group, the PPV
of PSA alone was 20.6% (284/1378). The CDR ‘parsimonious’ model (Method 2, cutpoint 1), yielded a positive predictive value of 55.3% (52/94). With a specificity of 96.2%
and a sensitivity of 18.3%, this model can reduce the number of unnecessary biopsies
from 1,092 to 92. With a specificity of 96.2%, this clinical decision rule model will
correctly identify more than 9 out of every 10 men who have do not have PC. In 1998,
the JH VA performed 1,610 biopsies. If one were to apply this clinical decision rule
(comparing PC stage B, C, D vs. stage A PC, PIN, BPH, and prostatitis) to the 1,378
subjects within this study, 52 of the 92 total biopsies (PPV= 55.3%) would have been
positive for PC (stage B,C,D) (PSA alone=PPV 44.7%). In addition, if this clinical
decision rule would have been employed, approximately 1,052 negative biopsies would
not have been performed. This would have resulted in decreased cost for the VA hospital
network, reduced anxiety and stress for patient, and a reduced risk of biopsy morbidity
(given the biopsies would have never been performed).
5.3 - Consistency with Literature
There were many areas of this study that were consistent with prior published,
peer reviewed studies. In particular, the proportion of PC that was localized to the
prostate is consistent with the stage shift phenomenon (increased amounts of pre-clinical
disease detected when compared to ways other than screening) seen with PC screening.
Stage A comprised 53.9 % of all the PC cases; Stage B 35.7 %; Stage C 7.8 %; and Stage
D 2.59 % (appendix: table 22). A stage shift towards less invasive disease at presentation
has been attributed to PC screening and this scenario was seen in this study.
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Secondly, all laboratory biomarkers demonstrated ‘movement’ in the direction
away from the ‘normal’ value that is consistent with previous literature and is
biologically plausible.101 For instance, PSA has been known to be elevated in both
cancerous and non-cancerous prostate conditions.1 This was seen in this study, as the
range of the mean PSA value increased from 7.67 (prostatitis) to 44.03 (stage D PC).
Multiple published studies have reported that a low hemoglobin value is an independent
risk factor for deleterious survival outcomes in patients with hormone refractory prostate
cancer.91 In addition; the correlation between PC and hematologic disorders has been long
recognized for its clinical significance, with anemia a frequent clinical manifestation of
advancing PC.101 In this study, the laboratory parameters HGB, RBC count, and MCV
(all indicators of hematologic state) demonstrated values below their normal reference
range (in patients with clinically relevant PC). When comparing the subjects with
histologically confirmed prostatitis to patients with histologically confirmed stage C PC,
the difference becomes evident. HGB decreased from 14.27 to 12.59, RBC count
decreased from 4.67 to 4.58, and MCV decreased 90.78 to 90.23 (HGB and RBC count
were statistically significant trends), respectively. In addition, it has been previously
described that decreased creatinine has been linked to decreased muscle mass and severe
liver disease (seen in patients with advancing PC).35 In this study, creatinine
demonstrated a decreasing trend as PC stage increased (1.16 to 1.13), although it was not
statistically significant.
African-American ethnicity increased the risk of PC in men undergoing biopsy.
There was an 83% increase in the risk of PC for African-American men when compared
to Caucasian men. This is consistent with previous literature which describes PC
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incidence and mortality rates as disproportionately higher in African-American males
than white males in the United States (up to two times higher).44
Advancing age is one of three non-modifiable risk factors for PC.10 The incidence
and prevalence of prostate cancer increases as men become older.10 In this study, the
mean age of subjects in this study was not significantly different. However, a one year
increase in age did increase the odds of PC development by 2% (which was statistically
significant).
5.4 - Internal Validity
There were specific study limitations that were identified during the performance
of this study. Concerns with selection bias, incomplete data, misclassification of the
outcome, and uncontrolled confounding were acknowledged and are outlined below. In
addition, the perceived study strengths are outlined as well.
5.4.1- Selection Bias
One concern of this study was the potential for selection bias on obtaining
prostate biopsies. It was believed that clinicians within the VA network follow an
algorithm for sending patients for prostate biopsy. If a patient had an elevated PSA test,
they would be referred onward for prostate biopsy. However, in the JH VA, do all men
with an elevated PSA actually undergo prostate biopsy? As a check for internal validity
(and to ensure selection bias is not present), further evaluation of this question was
warranted. A search through the VISTA system was initiated to capture all PSA lab tests
performed for the years 1998, 2000, and 2002. They were then sub-categorized for PSA
values greater than 4ng/dL. This list was then crossed referenced against the list of
patients that had a recorded prostate biopsy during the study period (1998-2004)
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(SNOMED codes: 77220, 77103, 77102, 77101, 77110, 77105, 77350, 77230, 77210,
77300, 77200, 77240, 77104, 77100, 77000, 77900, and 77250). During this period, there
were 442,000 PSA tests performed at the JH VA, of which 3,425 patients had a value of
greater than 4ng/dL. Of the 3,425 patients with elevated PSA values, 1,610 had
undergone a prostate biopsy, and 1,810 had not (52.9%). Further investigation was
needed to explain why over half of the patients with elevated PSA values did not undergo
a biopsy. After much investigation and discussion with both JH VA Urology and
Pathology physicians, it was determined that approximately 75% of the 1,810 elevated
PSA values were of patients status post PC treatment (prostatectomy, radiation,
cryotherapy, etc.), and had actually undergone a prostate biopsy before the timeline of
this study, thus their biopsy results were not captured during the original VISTA search.
It is important to note that PSA is used more frequently as a tool for post PC treatment
follow-up than for screening.106 It is considered the standard of care for all post-treatment
PC patients to have an annual PSA draw to monitor for refractory prostate cancer. In
addition, it was estimated that 12.5% of all patients that are found to have elevated PSA
values through the VA medical network choose to have their care outside the VA
network. Therefore, their specific treatment information is not available for analysis. It is
estimated that 88-90 % of all participants in this study found to have an elevated PSA
through screening were referred for evaluation via prostate biopsy.
5.4.2 - Incomplete data
Certain laboratory biomarkers had incomplete data which lead to the exclusion of
these variables for analysis and interpretation. Although clinicians often obtain a
complete blood count (CBC), basic metabolic panel (BMP), and urinalysis (UA) at the
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time of the screening PSA test, certain laboratory assays (e.g. PT/aPTT, and Folate) are
not routinely included in these panels, thus they are not requested. Both PT and aPTT are
used to evaluate the coagulation system, with increasing levels of both being an
independent predictor of DIC (a systemic condition seen occasionally with metastatic
PC).75 High plasma levels of Folate has been previously reported as both protective and
as a risk factor for PC development.125 Given the plausible links to PC, they were of
particular interest for this study. There are no current guidelines that recommended
additional laboratory tests for PC screening; therefore clinicians do not make the request
for such additional tests. This lack of data limits the strength of the analysis and
interpretation of the results.
5.4.3 - Misclassification of outcome
Although each prostate biopsy was evaluated by two or more trained pathologists,
the possibility that misclassification of disease status (i.e. patients who have PC were
classified as ‘no PC’) does exist. Given that the outcome variable (PC yes or no) is
determined by the results of a prostate biopsy, and that the biopsies themselves are a
sampling of the entire prostate, there is a chance that the biopsy did not contain cancerous
cells, yet the prostate itself does. If this scenario occurred, the patient would be
categorized as ‘no PC’, when in fact they do have PC. When there are two outcome
categories being compared (in this case, “PC yes/no”), this misclassification can bias the
association either away or towards the null hypothesis. However, it is unlikely that an
individual would be categorized as having PC if the carcinoma was not present on
histological sample. Therefore if misclassification is present, it is more likely that a
patient with PC is misclassified as not having prostate cancer, than a patient without PC
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being classified as having the disease.
5.4.4 - Uncontrolled confounding
Certain variables that were initially recommended for collection were not
available for analysis; therefore this study’s results may be a result of confounding.
Specifically, information on family history of PC was found to be lacking in both the
urological and general clinic patient encounter notes; and family history on any medical
condition was available in less than 50 % of the study participants. In addition, social
history (tobacco and alcohol use) and socio-economic status (which have been previously
described as potential modifiable risk factors for PC) were initially scheduled for
evaluation. Unfortunately, this information was also missing on a large percentage of the
study participants (75%) and therefore unavailable for analysis.
5.4.5 – Study Strengths
The strengths of this study include the data quality, study population size, biologic
plausibility, and the type of analysis performed.
The quality of the data was increased in that the diagnosis of prostate disease
status was discerned from histologic evaluation of biological materials obtained from
invasive prostate biopsy by at least two highly trained clinical pathologists. In addition,
the use of laboratory data eliminates the chance of recall and interviewer bias entering the
study. The ethnicity of each study participant was obtained from two different data sets
to increase reliability of the variable.
The study population was 1,378 subjects, of which 616 were prostate cancer
patients. This high proportion of cases increases overall study power and statistical
efficiency (more likely to have stable parameter estimates and identify effect
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modification between independent variables). This increased study power allowed for
stratification on key parameters, such as PC stage and ethnicity.
The results are biologically plausible. The results of this study are consistent with
what existing knowledge. It is accepted within the medical community that there is a
relationship between PC and systemic diseases that occur in presence of both local and
metastatic spread of PC.101 Moreover, it has been demonstrated that the specified
laboratory biomarkers evaluated in this study are highly correlated with the systemic
diseases related to PC spread.21
The types of analysis performed in this study included both logistical and linear
regression modeling. These modeling strategies allow for controlling of known PC risk
factors and other independent variables, thereby providing a linear combination of
optimally weighted independent variables that best explain the outcome variable.
5.5 - External Validity
The study’s subjects were men treated within the VA Healthcare networks located
in Tampa, Florida. The demographic characteristics of the population under study are
similar to that of the national VA system. The group are primarily Caucasian middle-aged
veterans (mean=68 y/o, SD=12) with an education attainment level of at least four years
of high school, or some college attendance.36
Approximately 2.5 million individuals receive all or part of their healthcare needs
from the VA medical system, and the Tampa Florida VA healthcare network handles on
average a total of 1,718,528 male patient encounters each year.36 Given the above, this
study’s subjects are believed to be representative of the national male VA population.
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5.6 - Public Health Importance and Future Directions
Men with PC have been described as falling in to one of four groups, and
screening can only benefit one of the groups. The first group consists of men with
normally progressing disease that is identified clinically; the second group includes men
with PC that advances very rapidly. For the above two groups, screening is of no benefit.
The third groups contains men with screen-detected PC that would have never advanced
to clinically relevant disease, therefore they are exposed to unnecessary procedures and
treatments. Lastly, group four contains asymptomatic men who have PC identified
through screening and receive beneficial outcomes that otherwise would have been
deprived if not for the screening.10 One difficulty in PC screening is identifying group 4
relative to group 3. This study results suggest evaluating four laboratory biomarkers
(HGB, RBC count, MCV, creatinine) in conjunction to a PSA value of >4ng/dL might
increase the validity of the PC screening process. This has important implications,
especially if PSA is used as a cost effective PC screening program. The overlap of PSA
values in men with PC and non-cancerous prostate conditions has been well documented.
This study provides a glimpse of the potential benefit that these additional lab parameters
can provide.
Future directions should first begin with repeating this study on multiple VA data
sets collected from different VA clinics around the U.S. Are the findings similar in data
sets that originate from a different geographic location? Do they vary in VA data sets that
are from communities with different age distributions, or in areas with higher proportions
of African American men? Individuals considered at high risk for PC include men with a
positive family history; advancing age, and African-Americans.10, 106 Does this clinical
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decision rule perform better for these high risk subsets? Can it address previous
descriptive epidemiology that describes PC as affecting African-American men in more
aggressive nature, and at an earlier age? Moreover, capturing information on PC family
history is of paramount importance. Would the employment of this clinical decision rule
result in a significant decrease of prostate biopsy numbers without increasing the false
negatives? Does the duration of disease affect the degree of change for each biomarker,
and by how much?
Stratification analysis techniques can provide additional insight on high risk
patients and exposures, and although this study contained large numbers of patients with
PC and non-cancerous prostate conditions (N=1,378), future studies should include a
larger sample size, given that it will facilitate further stratification. Only after replicating
this study on different data sets (and demonstrating consistency of findings), should a
randomized prospective study be considered.
Perhaps the most important question yet to be answered is this: Given an elevated
PSA value and values of the specified laboratory biomarkers that yield a probability
value above the cut-off point, would a clinician confidently recommend a prostate biopsy
for his/her patient? Moreover, if there is a lack of change in the biomarkers, would a
clinician confidently recommend a more conservative, expectant observation (watchful
waiting) approach?
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Appendix:
The following case examples provide a glimpse of the real world application of
the proposed clinical decision rule outlined in this study.
Case example 1: (For this example, method 1, cut-point 1 will be utilized)
The probability of this cut-point is .45, therefore the Log OR p/1 – p = .45/1-.45, thus the
cut-point is -0.08. (If the number yielded from equation is above this value, the patient
should be referred for prostate biopsy). The patient is a 67 year old, African American
male with a recent PSA test value of 5.2 (ng/dL). Additional lab work: HGB 10.5, RBC
count 4.45, MCV 94.1, Albumin 4.0, Creatinine 1.12, and a positive test for Hematuria
(at least 1 RBC per high powered field)
Prob..45/.55=
-0.08 (cutpoint)

Patients value

Parameter estimate

Pt. value
*Parameter
estimate

HGB
RBC
Black

10.5
4.45
(Yes=1) 1

-0.3519
0.9227
0.6336

-3.69
3.65
0.63

Hematuria
Age

(Yes=1) 1
67

-0.2874
0.0196

-0.29
1.31

Albumin
PSA
Creatinine
MCV

4
5.2
1.12
94.10

0.2871
0.0408
-0.4393
0.0663
sum of B*value
plus intercept= Total
Score

1.15
0.21
-0.49
6.05
8.53

Intercept
-7.95

.58

Patients CDR Total Score 0.58 > -0.08. Recommendation? Send for Biopsy
Figure 12. Case Example 1 using Method 1, cut-point 1
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Case example 2: (For this example, method 2, cut-point 1 will be utilized)
The probability of this cut-point is .41 therefore the Log OR p/1 – p = .41/.59, thus the
cut-point is -0.16 (If the number yielded from equation is above this value, the patient
should be referred for prostate biopsy). The patient is a 75 year old, Caucasian male with
a recent PSA test value of 4.3 (ng/dL). In addition, he had additional lab work to include
a HGB, RBC count, MCV, and Creatinine:
Prob..41/1-.41
= -0.16

Patients value

Parameter estimate

HGB
RBC
Black
Age
PSA
Creatinine
MCV

15.2
4.50
(Yes=1) 0
75
4.3
1.65
90.00

-0.378
0.764
0.361
0.018
0.033
-0.601
0.050
sum of B*value
plus intercept= Total
Score

Pt. value
*Parameter
estimate
-5.74
3.44
0.00
1.35
0.129
-0.99
4.5
2.69
-2.41

Patients CDR Total Score -2.41< -0.16. Recommendation? No Biopsy
Figure 13. Case Example 2 using Method 2, cut-point 1
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Intercept
-5.10

Case example 3: (For this example, method 3, cut-point 1 will be utilized)
The probability of this cut-point is .45, therefore the Log OR p/1 – p = .45/1-.45, thus the
cut-point is 123456. (If the number yielded from equation is above this value, the patient
should be referred for prostate biopsy). The patient is a 87 year old, African American
male with a recent PSA test value of 14.7 (ng/dL). In addition, he had additional lab work
to include a HGB, RBC count, MCV, and Creatinine.
Prob..42/1-.42
= -0.14

Patients value

HGB
RBC
Black
Age
PSA
Creatinine
MCV

11.2
4.12
(Yes=1) 1
87
14.7
0.98
89.51

Parameter estimate

Pt. value
*Parameter
estimate

-0.472
-5.29
1.105
4.55
0.609
0.61
0.024
2.09
0.054
0.79
-0.815
-0.80
0.066
5.91
sum of B*value
7.86
plus intercept= Total
1.06
Score
Patients CDR Total Score 1.06 > -0.14. Recommendation? Send for Biopsy

Figure 14. Case Example 3 using Method 3, cut-point 1
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Intercept
-6.80

Prostate
Cancer
Stage A
Stage B
Stage C
Stage D
PIN
BPH
Prostatitis

Total
prostate
biopsies

All
Ethnicity

White

AfricanAmerican

Hispanic

Other

Unknown/Refused

Totals

616
44.7%
(332)
53.9%
(220)
35.7%
(48)
7.80%
(16)
2.59%
138
10.0%
282
20.5%
342
25.0%
1,378

428
43.9%
(238)
55.6%
(149)
34.81%
(31)
7.24%
(10)
2.34%
99
10.15%
211
21.6%
237
24.3%
975

67
57.3%
(34)
50.7%
(22)
32.8%
(7)
10.4%
(4)
6.00%
13
11.1%
19
16.24%
18
15.4%
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28
39.4%
(15)
53.6%
(11)
39.3%
(1)
3.5%
(1)
3.5%
7
9.86%
14
19.7%
22
31.0%
71

15
33.3%
(11)
73.3%
(3)
20.0%
(1)
6.66%
(0)
0.00%
6
13.3%
10
22.2%
14
31.1%
45

78
45.9%
(34)
43.6%
(35)
44.9%
(8)
10.2%
(1)
1.3%
13
7.65%
28
16.5%
51
30.0%
170

616

Table 22: Baseline data by Ethnicity/Histologic biopsy.
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332
220
48
16
138
282
342
N=1,378
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